Annotated Trial Design Page 1 of 68

NIDA

Annotated Design For Trial: ctn0027

Protocol: CTN-0027

Generated By InForm Architect[™]

August 30, 2010 12:53PM

Annotated Trial Design Page 2 of 68

Assessment	CRF	Study: ctn0027 Baseline/Screening (SCR)		Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 7	Week 8	Week 9	Week 10	Week 11	Week 12	Week 13	Week 14	Week 15	Week 16	Week 17	Week 18	Week 19	Week 20	Week 21	Week 22	Week 23	Week 24	Week 28	Week 32	Cross Active	Conflic
		[S]	(WKO) [S]		(WK2) [S]	(WK3) [S]	(WK4) [S]	(WK5) [S]			(WK8) [S]		(WK10) [S]	(WK11) [S]	(WK12) [S]		(WK14) [S]	(WK15) [S]			(WK18) [S]					(WK23) [S]	(WK24) [S]	(WK28) [S]	(WK32) [S]	Study (CAS) [S]	[U/R/D
Research Session Attendance	RSA	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
Informed Consent	INF	2																													
Demographics	DEM	3																													
Alcohol Breathalyzer / Urine Drug Screen	UDSAB	4		2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		2		
DSM-IV Checklist Summary	DSM-IV	5																													
Exclusion Criteria	EXC	6																													
Inclusion Criteria	IXC	7																													
Labs and Urinalysis	LAB	8-RF		3-RF	3-RF		3-RF				3-RF				3-RF				3-RF				3-RF				3-RF		3-RF		
Medical and Psychiatric History	MDH	9																													
0 Physical Exam	PEX	10																									4				
Pregnancy and Birth Control Assessment	PBC	11-DF																													
2 Risk Behavior Survey	RBS	12													5												6				
3 RISK BEHAVIORS SURVEY (2 of 2)	RBSMale	13-DF													6-DF												7-DF				
4 Risk Behaviors Surveys (2 of 2)	RBSFemale	14-DF													7-DF												8-DF				
5 Risk Behavior Surveys (2 of 2)	RBSAII	15-DF													8-DF												9-DF				
6 Substance Use	TFB-Lead	16					6				6				10				6				6				11		5		
7 Time Line Follow Back Active Study	TFB	17-RF-DF					7-RF- DF				7-RF- DF				11-RF- DF				7-RF-DF				7-RF-DF				12-RF- DF		6-RF-DF		
8 Vital Signs	VSF	18		5	5		8				8				12				8				8				13		7		
9 Alcohol Breathalyzer	ABZ		2																												
0 Randomization	RAN		3																												
1 Study Drug Dose Log	DOS		4-RF	4-RF	4-RF	3-RF	5-RF	3-RF	3-RF	3-RF	5-RF	3-RF	3-RF	3-RF	9-RF	3-RF	3-RF	3-RF	5-RF	3-RF	3-RF	3-RF	5-RF	3-RF	3-RF	3-RF	10-RF				
2 Clinical Opiate Withdrawal Scale - Predose	COWS1		5																												
3 Clinical Opiate Withdrawal Scale - Postdose	COWS2		6																												
4 Pregnancy and Birth Control Assessment	PBC		7-DF				4-DF				4-DF				4-DF				4-DF				4-DF				5-DF	2-DF	4-DF		
5 Prior and Concomitant Medications	PCM																													1	
6 Adverse Events	AE																													2-RF	
7 Genetics	GEN																													3	\perp
8 Serious Adverse Event	SAE																													4-RF	
9 Serious Adverse Event, 12, 13	SAE2a																													5-RF	
O Serious Adverse Event (continued)	SAE2b																													6-RF	
Serious Adverse Event (continued), page 22	SAE3																													7-RF	
2 Pregnancy and Outcome	POC																													8	
3 Pregnancy and Outcome Contd	POC NB																													9	
4 Protocol Violation	PVL																													10-RF	1
5 Study Medication Change Form	MED																													11	
6 Study Termination	TERM				1																				—					12	1

Annotated Trial Design Page 3 of 68

	ctn0027 : SYSTEM SCREENING (SCR) Protocol Number - NIDA-CTN-0027						
-	NODE	A2 (CTN0027CDD:t_frmScr.txtScrPatInit)					
2.	Participant ID Please enter 4 numeric ID	A4 (CTN0027CDD:t_frmScr.tePATNUM)					
3.	Date of Birth:	Req V / Req V / Req V (1900-1992) (CTN0027CDD:t_frmScr.SCR003)					
4.	Sex:	(CTN0027CDD:t_frmScr.SCR004) [1]					

Item Design Notes:									
Item No.	Design Note								
1.	mapped from Screening form to INF form								

CDD: CTN0027CDD	Table: t_frmScr	Key Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
tcPATNUM	STRING(4) - A4	
SCR003	DATE - DDMONYYYY	
SCR004	NUMERIC	
txtScrPatInit	STRING(2) - A2	

Annotated Trial Design Page 4 of 68

ct	ctn0027 : SYSTEM ENROLLMENT (Enr)						
St	Study Enrollment						
1.	Participant ID [editable]	A25	Please do not enter or modify data on this field NOTE: If this box does not have a value, please ensure that the Participant Id on the Screening Form has 4 numbers.	(CTN0027CDD:t_frmEnr.txtPInumber)			

Item Design Notes:							
Item No.	Design Note						
1.	mapped from Enrollment form to PI form						

CDD: CTN0027CDD	Table: t_frmEnr Key	y Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
txtPInumber	STRING(25) - A25	

Annotated Trial Design Page 5 of 68

ctı	ctn0027 : Research Session Attendance (RSA)						
1.		(CTN0027CDD:t_frRSA.RSA001) [0] ○ 0 No [1] ○ 1 Yes 2. Date of Visit: NReq / NReq (2006-2010) (CTN0027CDD:t_frRSA.RSA002)					
2.*	3. Comments (include reason for session if it is an unscheduled visit)	A200 (CTN0027CDD:t_frRSA.RSA003)					
*	Item is not required						

CDD: CTN0027CDD Table: t_frRSA Key Type: PATIENTVISIT						
Column Name	Column Data Type	Design Note				
RSA001	NUMERIC					
RSA002	DATE - DDMONYYYY					
RSA003	STRING(200) - A200	ĺ				

Annotated Trial Design
Page 6 of 68

ctn0027 : Informed Consent (INF)						
Patient Information						
***WARNING: ANY CHANGES MADE TO THESE FIELDS BELOW WILL CHANGE THE IDENTIFICATION OF THIS SUBJECT - Changes that make these fields empty will not be acted upon and the prior values will remain for the purpose of identification. ***						
Patient Number	A15 (CTN0027CDD:t_frINF.txtPInumber)					
	siteno-NODE-Participant ID					
Node	A3 (CTN0027CDD:t_frINF.txtScrPtInitials)					
nformed Consent						
Date informed consent signed:	Req / Req (2006-2010) (CTN0027CDD:t_frINF.INF001)					
	etient Information **WARNING: ANY CHANGES MADE TO THESE FIELDS BELOW WILL CHANGE THE IDENTIFICATION OF THIS SUBJECT - Changes that make these fields empty will r Patient Number Node formed Consent					

Item Desi	gn Notes:
Item No.	Design Note
1.	mapped from Enrollment form to PI form
2.	mapped from Screening form to PI form

CDD: CTN0027CDD	Table: t_frINF Key T	ype: PATIENTVISIT
Column Name	Column Data Type	Design Note
txtPInumber	STRING(15) - A15	
txtScrPtInitials	STRING(3) - A3	
INF001	DATE - DDMONYYYY	

Annotated Trial Design Page 7 of 68

tn0027 : Demographics (DEM)			
Assessment Date	Req / Req / Req (2006-2010) (CTN0027CDD:t_frDEM.VISITDT)		
mographics			
1. Date of Birth:	Req / Req / Req (1900-1992) (CTN0027CDD:t_frDEM.DEM001)		
2. Sex:	(CTN0027CDD:L_frDEM.DEM002) [1] ○ 1 Make [2] ○ 2 Female		
3. Ethnicity:	(CTN0027CDD:t_frDEM.DEM003a) [1]		
	[2] O2 Not of Spanish origin, Hispanic or Latino		
4. Race (check all that apply):	(CTM0027CDD:_frDEM_DEM004b) [1]		
	(CTN0027CDD:t_frDEM.DEM004f) [6] □ other (specify): A50		

CDD: CTN0027CDD		
Column Name	Column Data Type	Design Note
DEM004b5	STRING(255)	
DEM004b6	STRING(255)	
DEMO01	DATE - DDMONYYYY	
DEM002	NUMERIC	
DEM003a	NUMERIC	
DEM004g	STRING(255)	
DEM004h	STRING(255)	
DEM004b7	STRING(255)	
DEM004d1	STRING(255)	
DEM004d2	STRING(255)	
DEM004d3	STRING(255)	
DEM004d4	STRING(255)	
DEM004d5	STRING(50) - A50	
DEM004e	STRING(255)	
DEM004f	STRING(255)	
DEM004fs	STRING(50) - A50	
DEM004b8	STRING(50) - A50	
DEM004c	STRING(255)	
DEM004d	STRING(255)	
VISITDT	DATE - DDMONYYYY	
DEM003b2	STRING(255)	
DEM003b3	STRING(255)	
DEM003b4	STRING(255)	
DEM003b5	STRING(50) - A50	
DEM004a	STRING(255)	
DEM004b	STRING(255)	

Annotated Trial Design Page 8 of 68

DEM004b1	STRING(255)	
DEM004b2	STRING(255)	
DEM004b3	STRING(255)	
DEM004b4	STRING(255)	
DEM003b1	STRING(255)	

Annotated Trial Design Page 9 of 68

ctr	n0027 : Alcohol Breathalyzer / Urine Drug Screen (UDSAB)	
Alc	ohol Breathalyzer	
1.	Was an Alcohol Breathalyzer performed successfully?	(CTN0027CDD:t_frUDSAB.AB001) (D) © No
2.*	2. Comments:	A200 (CTN0027CDD:t_frUDSAB.AB002)
Urir	ne Drug Screen	
-	Was a Urine Drug Screen Performed?	(CTN0027CDD:t_frUDSAB.UDS001)
	(Only answer questions 2, 3, and 4 if answer to this question is Yes or Lost Sample)	[O] ○ No
L.		[2] O2 Lost sample
4.*	2. Date urine collected:	Req / Req / Req (2006-2010) (CTN0027CDD:t_fruDSAB.UDS002)
Ĺ	3. Was urine temperature within expected range (temperature 92°F ≤ X ≤ 96°F OR 33.3°C ≤ X ≤ 35.5°C) ?	(CTN0027CDD:t_frUDSAB.UDS003) OJ
6.*	4. Was the urine collection supervised?	(CTN0027CDD:t_frUDSAB.UDS004) [0] 0 No [1] 0 1 Yes [99] 0 99 Unknown
Sele	ect the result of the screen for each substance below.	
7.	5. Amphetamines (AMP):	CTN0027CDD:t_frUDSAB UDS005 f-5
8.	6. Benzodiazapines (BZO):	CTN0027CDD:t_frUDSAB.UDS006 F-5 0 - 5 Not Assessed CTN0027CDD:t_frUDSAB.UDS006A CTN0027CDD:t_frUDSAB.UDS006A
9.	7. Methadone (MTD):	CTN0027CDD:t_frUDSAB UDS007) f-5
10.	8. Oxycodone:	CTN0027CDD:t_frUDSAB UDS008 [-5]
11.	9. Cocaine metabolites (COC):	(CTN0027CDD:L_frUDSAB.UDS009)
12.	10. Methamphetamine (M-AMP):	CTN0027CDD:t_frUDSAB_UDS010)
13.	11. Opiate 300:	(CTN0027CDD:L_frUDSAB_UDS011) [-5] ○ -5 Not Assessed [0] ○ 0 Negative [1] ○ 1 Positive [2] ○ 2 Unclear Specify (CTN0027CDD:L_frUDSAB.UDS011A) A50
	12. Cannabinoids (THC):	CTN0027CDD:L_frUDSAB UDS012) f-5j
15.	13. Propoxyphene:	(CTN0027CDD::L_frUDSAB.UDSD13) I-5]
*	Item is not required	

CDD: CTN0027CDD	Table: t_frUDSAB	Key Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
UDS005	NUMERIC	
UDS005A	STRING(50) - A50	
AB001	NUMERIC	
AB001A	DATE - DDMONYYYY	
AB001B	FLOAT - F5.3	
AB002	STRING(200) - A200	
UDS001	NUMERIC	
UDS001A	NUMERIC	

Annotated Trial Design Page 10 of 68

UDS001B	STRING(50) - A50	[
UDS002	DATE - DDMONYYYY	
UDS003	NUMERIC	
UDS004	NUMERIC	
UDS011A	STRING(50) - A50	
UDS012	NUMERIC	
UDS012A	STRING(50) - A50	
UDS013	NUMERIC	
UDS006	NUMERIC	
UDS006A	STRING(50) - A50	
UDS007	NUMERIC	
UDS007A	STRING(50) - A50	
UDS008	NUMERIC	
UDS008A	STRING(50) - A50	
UDS009	NUMERIC	
UDS009A	STRING(50) - A50	
UDS010	NUMERIC	
UDS010A	STRING(50) - A50	
UDS011	NUMERIC	
UDS013A	STRING(50) - A50	

Annotated Trial Design Page 11 of 68

ctn0027 : DSM-IV Checklist Summary (DSM-IV)		
Assessment Date	Req / Req (2006-2010) (CTN0027CDD:L_frDSM.DSMADT)	
DSM-IV Checklist Summary		
2. Opiates:	(CTN0027CDD:t_frDSM.DSMOPI) [1] Opependence [2] Ohouse [3] No diagnosis	
3. Alcohol:	(CTN0027CDD:t_frDSM.DSMAL) [1] Opependence [2] Abuse [3] No diagnosis	
4. Amphetamines:	(CTN0027CDD:t_frDSM.DSMAM) [1] Opependence [2] Abuse [3] No diagnosis	
5. Cannabis:	(CTN0027CDD:_frDSM.DSMCA) [1] Opependence [2] Ohouse [3] No diagnosis	
6. Cocaine:	(CTN0027CDD:t_frDSM.DSMCO) [1] Opependence [2] OAbuse [3] ONo diagnosis	
7. Sedatives:	(CTN0027CDD:t_frDSM.DSMSE) [1] Opependence [2] Ohouse [3] No diagnosis	

CDD: CTN0027CDD	Table: t_frDSM Key	Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
DSMADT	DATE - DDMONYYYY	
DSMOPI	NUMERIC	
DSMAL	NUMERIC	
DSMAM	NUMERIC	
DSMCA	NUMERIC	
DSMCO	NUMERIC	
DSMSE	NUMERIC	

Annotated Trial Design Page 12 of 68

n0027 : Exclusion Criteria (EXC)	T
Assessment Date	Req / Req / Req (2006- (CTN0027CDD: t_frEXC.VISITE 2010)
clusion Criteria ra list of abnormalities, please refer to the Operations Manual. ee Appendix D to the Protocol.	
1. Does the participant have AST or ALT values > 5 times the upper limit of normal as per the criteria of the laboratory?	(CTN0027CDD:t_frEXC.EXC001) [0] 0 No [1] 0 1 Yes
2. Does the participant have ALP > 3 times the upper limit of normal as per the criteria of the laboratory?	(CTN0027CDD:t_frEXC.EXC002) [0] 0 No [1] 1 Yes
3. Does the participant have any documented past or present history of ascites, presence of esophageal or gastric varices, hepatic encephalopathy or other signs of significant liver disease as indicated by a Model for Endstage Liver Disease score (Kamati et al., 2001) of >= 11?	O (CTN0027CDD:t_frEXC.EXC003) [0] 0 No [1] 1 Yes
4. Does the participant have a total bilirubin > 2.0 mg/dL (patients with documented Gilbert's syndrome will be included)?	(CTN0027CDD:t_frEXC.EXC004) [0] 0 No [1] 1 Yes
5. Does the participant have a prothrombin time more than 3 seconds prolonged?	(CTN0027CDD:t_frEXC.EXC005) [0] 0 No [1] 1 Yes
6. Does the participant have an albumin level less than 2.5 g/dL?	(CTN0027CDD:t_frEXC.EXC006) [0] 0 No [1] 0 1 Yes
7. Does the participant have any cardiopathy or risk factor listed below without evdence of a normal ECG* with report performed within 6 months prior to first study medication dose? a Congestive heart failure b Left ventricular hypertrophy c Bradycardia d Hereditary QT prolongation e Uncorrected electrolyte imbalance f Concomitant medications which are know to result in QT interval prolongation.**	(CTN0027CDD:1_frEXC.EXC007) [0] ○ 0 No [1] ○ 1 Yes
8. Does the participant have an acute medical condition that would make participation, in the opinion of the study physican, medically hazardous (e.g., unstable pancreatic, cardiovascular, or renal disease; significant anemia)?	(CTN0027CDD:t_frEXC.EXC008) [0] 0 No [1] 1 Yes
9. Does the participant have known allergy or sensitivity to BUP, naloxone, or MET, or to any of the inactive ingredients in the study medications (including lactose, mannitol, cornstarch, povidone K30, citric acid, sodium citrate, FD&C Yellow No 6 color, magnesium stearate, Acesulfame K sweetener/?	(CTN0027CDD:t_frEXC.EXC009) [0] 0 No [1] 1 Yes
10. Does the participant have a known diagnosis of acute psychosis, severe depression or imminent suicide risk as determined via clinical interview by study physician or surrogates?	(CTN0027CDD:t_frEXC.EXC010) [0] 0 No [1] 1 Yes
11. Does the participant have a DSM-IV diagnosis of dependence on benzodiazapines or alcohol requiring immediate medical attention?	(CTN0027CDD:t_frEXC.EXC011) [0] 0 No [1] 0 1 Yes
12. Does the participant have a DSM-IV diagnosis of dependence on other depressants, or stimulants requiring immediate medical attention?	(CTN0027CDD:t_frEXC.EXC012) [0] 0 No [1] 0 1 Yes
13. Has the participant participated in an investigational drug study within the past 30 days?	(CTN0027CDD:t_frEXC.EXC013) [0] 0 No [1] 0 1 Yes
14. Has the participant had a treatment with MET, BUP/ NX, or BUP for more than 15 of the past 30 days (illicit use of these medications is allowed)?	(CTN0027CDD:t_frEXC.EXC014) [0] 0 No [1] 0 1 Yes
. 15. Does the participant have pending legal action that could prohibit study participation?	(CTN0027CDD:t_frEXC.EXC015) [0] 0 No [1] 0 1 Yes
16. Is the participant unable or unwilling to comply with study requirements?	(CTN0027CDD:t_frEXC.EXC016) [0] 0 No [1] 0 1 Yes
17. Is the participant unable or unwilling to remain in the local area for duration of treatment?	(CTN0027CDD:t_frEXC.EXC017) [0] 0 No [1] 0 1 Yes
18. Does the participant have poor venous access such that venipuncture could not be accomplished from a vein in an extremity during eligibility?	(CTN0027CDD:t_frEXC.EXC018) [0]
. 19. If female, is she pregnant or lactating?	(CTN0027CDD:t_frEXC.EXC019) [0] ○ 0 No [1] ○ 1 Yes [96] ○ NA

CDD: CTN0027CDD Table: t frEXC Key Type: PATIENT		
Column Name	Column Data Type	Design Note
EXC012	NUMERIC	
EXC013	NUMERIC	
EXC014	NUMERIC	
EXC015	NUMERIC	
EXC016	NUMERIC	
EXC017	NUMERIC	
EXC018	NUMERIC	
EXC019	NUMERIC	
EXC008	NUMERIC	
EXC009	NUMERIC	
EXC010	NUMERIC	
EXC011	NUMERIC	
VISITDT	DATE - DDMONYYYY	
EXC001	NUMERIC	
EXC002	NUMERIC	
EXC003	NUMERIC	
EXC004	NUMERIC	
EXC005	NUMERIC	
EXC006	NUMERIC	
EXC007	NUMERIC	

Annotated Trial Design Page 13 of 68

ctn0027 : Inclusion Criteria (IXC)	
1. Assessment Date	Req / Req / Req (2006-2010) (CTN0027CDD:t_fIXC.VISITDT)
Inclusion Criteria	
2. 1. Is the participant 18 years of age or older?	(CTN0027CDD:t_rixC.IXC001) [0] © 0 No [1] © 1 Yes
3. 2. Does the participant meet DSM-IV criteria for opioid dependence?	(CTN0027CDD:t_frIXC.IXC002) [0] 0 No [1] 0 1 Yes
4. 3. Is the participant in good general health or, in case of a medical/ psychiatric condition requiring ongoing treatment, is the participant under the care of a physician willing to continue participant's medical management and to cooperate with study physicians?	(CTN0027CDD:t_friXC.IXC003) [0] 0 No [1] 0 1 Yes
5. 4. If female of childbearing potential, does the participant agree to use one of the following acceptable methods of birth control throughout the study: a oral contraceptives b barrier (diaphragm, cervical cap) with spermicide, or condom c intrauterine device (UID) d intrauterine progesterone contraceptive system (IUD) e levonorgestrel implant f medroxyprogesterone acetate contraceptive injection g contraceptive transdermal patch h hormonal vaginal contraceptive ring i surgical sterilization j complete abstinence from sexual intercourse?	(CTN0027CDD:L_friXC.IXC004) [0]
6. 5. Is the participant able to read and verbalize understanding and voluntarily sign the approved Informed Consent form prior to performance of any study-specific procedures?	(CTN0027CDD:t_friXC.IXC005) [0] 0 No [1] 0 1 Yes

CDD: CTN0027CDD Table: t_frIXC Key Type: PATIENTVISIT		
Column Name	Column Data Type	Design Note
IXC001	NUMERIC	
IXC002	NUMERIC	
IXC003	NUMERIC	
VISITDT	DATE - DDMONYYYY	
IXC004	NUMERIC	
IXC005	NUMERIC	

Annotated Trial Design Page 14 of 68

#	Assessment Date	Blood Chemistry	Hematology	Liver	Urine	Hepatitis	ITEM1	_L ITEM1		HIV test
_		1. —								
ľ	Assessment Date	Req 🗹	Req / Req (2006-2010) (CTN0027CDD:t	frLAB.VISITDT)						
*	. Blood Chemistry:	[97] O	DD: t_frLAB.LAB001a) of bone to Done te Drawn (2006- (CTN0027/ NReq / NReq 2010)	CDD:t_frLAB.LAB001b1	Time Drawn	24-hour clock (CTN0027CDD:t_fr	rLAB.LAB001b2) ((Repeat Test? CTN0027CDD:t_frLAB.LAB001b3) [O]	Accession (CTI Number A10	N0027CDD:t_frLAB.LAB0
*	2. Hematology:	[97] O		CDD:t_frLAB.LAB002b1	Time Drawn NReq NReq	24-hour clock (CTN0027CDD:t_fr	rLAB.LAB002b2) ((Repeat Test? CTN0027CDD:t_frLAB.LAB002b3) [O]	Accession (CTI Number A10	N0027CDD:t_frLAB.LAB0
* :). Liver tests:	[97] O		CDD:t_frLAB.LAB003b1	Time Drawn	24-hour clock (CTN0027CDD:t_fr	rLAB.LAB003b2) ((Repeat Test? CTN0027CDD:t_frLAB.LAB003b3) 70	Accession (CTI Number A10	N0027CDD:t_frLAB.LAB0
*	l. Urinalysis:	[97] 🔘		CDD: t_frLAB.LAB004b1	Time Drawn	24-hour clock (CTN0027CDD:t_fr	rLAB.LAB004b2) ((Repeat Test? CTN0027CDD:t_frLAB.LAB004b3) 70	Accession (CTI Number	N0027CDD:t_frLAB.LAB0
	i. Hepatitis serologies:	[97] O		CDD: t_frLAB.LAB005b1	Time Drawn	24-hour clock (CTN0027CDD:t_fr	rLAB.LAB005b2) (I	Repeat Test? CTN0027CDD:_frLAB.LAB005b3) 707	Accession (CTI Number A10	N0027CDD:t_frLAB.LAB0
	ia. Since the last visit, has the participant had a Hepatitis A v	[11 OY	CDD:t_frLAB.LAB005aa) S [0]							
!	ib. Since the last visit, has the participant had a Hepatitis B V	/accine? (CTN0027	CDD: t_frLAB.LAB005bb) s [0]							
*	b. HIV test:	[97] OI	CDL t_frLAB.LAB006s) bit Done te Drawn Req / NReq / NReq 2010)	CDD:t_frLAB.LAB006b1	Time Drawn	24-hour clock (CTN0027CDD:t_fr	rLAB.LAB006b2) ((Repeat Test? CTN0027CDD:t_frLAB.LAB006b3) TOJ	Accession (CTI Number	N0027CDD:t_frLAB.LAB0

CDD: CTN0027CD	D Table: t_frLAB Key	Type: PATIENT\
Column Name	Column Data Type	Design Note
LAB003b1	DATE - DDMONYYYY	
LAB003b2	DATE - HHMM	
LAB003b3	NUMERIC	
LAB003b4	STRING(10) - A10	
LAB004a	NUMERIC	
LAB004b1	DATE - DDMONYYYY	
LAB004b2	DATE - HHMM	
LAB004b3	NUMERIC	
LAB004b4	STRING(10) - A10	
LAB005a	NUMERIC	
LAB005bb	NUMERIC	
LAB006a	NUMERIC	
LAB006b1	DATE - DDMONYYYY	
LAB006b2	DATE - HHMM	
LAB006b3	NUMERIC	
LAB006b4	STRING(10) - A10	
LAB005aa	NUMERIC	
LAB002b1	DATE - DDMONYYYY	
LAB002b2	DATE - HHMM	
LAB002b3	NUMERIC	
VISITDT	DATE - DDMONYYYY	
LAB001a	NUMERIC	
LAB001b1	DATE - DDMONYYYY	
LAB001b2	DATE - HHMM	
LAB001b3	NUMERIC	

Annotated Trial Design Page 15 of 68

LAB001b4	STRING(10) - A10	
LAB002a	NUMERIC	
LAB003a	NUMERIC	
LAB005b3	NUMERIC	
LAB005b4	STRING(10) - A10	
LAB005b1	DATE - DDMONYYYY	
LAB005b2	DATE - HHMM	
LAB002b4	STRING(10) - A10	

Annotated Trial Design Page 16 of 68

	0027 : Medical and Psychiatric History (MDH)	I. — . — .		
1.	Assessment Date	Req 🗸 / Req 🛂 / F	Req (2006-2010) (CTN0027CDD:t_frMDH.VISI	TDT)
Medi	cal and Psychiatric History			
* NOT	E: Evidence for hypertension: If participant provides a blood pressure that is higher than 140	mm HG (systolic) over 90 mm	HG (diastolic) then they will be evaluated by the study physician	to determine if they have clinically significant hypertension that is not controlled.
	you ever been treated for or have a history of:			
_		(CTN0027CDD: t_frMDF	1.MDH001)	
		(History	
		rez O O No history		
		[0] 0 No history	If Yes: Specify	(CTN0027CDD: _frMDH.MDH001s)
			A200	
		[9] 09 Not evaluated	d	
3.	2. Allergies	(CTN0027CDD: t_frMDH		
		[0] 0 No history		
		[1] 0 1 Yes, history	A200	(CTN0027CDD: t_frMDH.MDH002s)
		[9] 09 Not evaluated	i	
4.	3. Liver problems	(CTN0027CDD: t_frMDH [0] 0 No history	H.MDH003)	
		[0] OU NO history		(CTN0027CDD:t_frMDH.MDH003s)
		[1] O 1 Yes, history	A200	(Citata) and citata (Citata)
		O Not ovaluates		
_		[9] 09 Not evaluated		
5.	4. Kidney problems	(CTN0027CDD:t_frMDH [0] 0 No history	H.MDH004)	
		[1] 0 1 Yes, history	A200	(CTN0027CDD:t_frMDH.MDH004s)
		[9] 09 Not evaluated	i	
6.	5. GI problems	(CTN0027CDD: t_frMDF		
		[0] 0 No history		
		[1] O 1 Yes, history	A200	(CTN0027CDD:L_frMDH.MDH005s)
		[9] 09 Not evaluated	i	
7.	6. Thyroid condition	(CTN0027CDD:t_frMDH [0] 0 No history	H.MDH006)	
		[1] O 1 Yes, history	A200	(CTN0027CDD: t_frMDH.MDH006s)
			1255	
		[9] 09 Not evaluated	i	
8.	7. Heart condition	(CTN0027CDD: t_frMDF		
		[10] 0 No history		
		[1] O 1 Yes, history	A200	(CTN0027CDD:t_frMDH.MDH007s)
		00 Not		
		[9] 09 Not evaluated		
9.	8. Asthma	(CTN0027CDD: t_frMDH [0] 0 No history	H.MDH008)	
		[1] O 1 Yes, history	A200	(CTN0027CDD:t_frMDH.MDH008s)
		[9] 09 Not evaluated	1	-
10.	9. High blood pressure hypertension*	(CTN0027CDD: t_frMDF		
		[0] 0 No history		(7)(0)(2)(2)(2)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)
		[1] O 1 Yes, history	A200	(CTN0027CDD:t_frMDH.MDH009s)
		[9] 09 Not evaluated		
11.	10. Any skin disease or problems with skin rashes	(CTN0027CDD: t_frMDH	H.MDH010)	
		[0] 0 No history	A200	(CTN0027CDD:t_frMDH.MDH010s)
			A200	
		[9] 09 Not evaluated	1	
12		(CTN0027CDD: t_frMDF		
		[01 0 No history		
		[1] O 1 Yes, history	A200	(CTN0027CDD:L_frMDH.MDH011As)
		[9] 09 Not evaluated		
13.	11b. Routine alcohol withdrawal symptoms	(CTN0027CDD:t_frMDF	H.MDH011B)	
		[0] 0 No history	A200	(CTN0027CDD: _frMDH.MDH011Bs)
		-	1200	
		[9] 09 Not evaluated	i	
14.	12. Schizophrenia			
	·	(CTN0027CDD:t_frMDH [0] 0 No history		
		[1] 0 1 Yes, history	A200	(CTN0027CDD:t_frMDH.MDH012s)
		9 Not evaluated	1	

Annotated Trial Design Page 17 of 68

		[9] 🔘			
15.		(CTN0027CDD: t_frMDH.MD [O] O No history [1] 1 Yes, history [A20]		(CTN0027CDD: t_frMDH.M	DH013s)
		[9] 09 Not evaluated			
16.		(CTN0027CDD:t_frMDH.MD [0] 0 No history [1] 1 Yes, history [9] 9 Not evaluated		(CTN0027CDD: t_frMDH.N	DH014s)
17.	15. Anxiety or Panic Disorder	(CTN0027CDD: t_frMDH.MD	H015)		
		[0] O No history [1] 1 Yes, history [A20	00	(CTN0027CDD:t_frMDH.N	DH015s)
		[9] 09 Not evaluated			
18.		(CTN0027CDD: t_frMDH.MD [0]		(CTN0027CDD: t_frMDH.N	DH016s)
19.		(CTN0027CDD: t_frMDH.MD [0]		(CTN0027CDD: t_frMDH.N	DH017s)
Med	ical and Psychiatric History (continued)				
	ere are other medical conditions or psychiatric/neurological histor	ry not previously mention			
20.*	19. Other 1	Other 1 (specify) A200	(CTN0027CDD:t_frMDH.MDH018	8) History specify A200	(CTN0027CDD::_frMDH.MDH018s)
21.*	20. Other 2	Other 2 (specify) A200	(CTN0027CDD:t_frMDH.MDH019	9) History specify A200	(CTN0027CDD:t_frMDH.MDH019s)
22.*	21. Other 3	Other 3 (specify) A200	(CTN0027CDD: t_frMDH.MDH020	D) History specify A200	(CTN0027CDD: t_frMDH.MDH020s)
23.*	22. Other 4	Other 4 (specify) A200	(CTN0027CDD: t_frMDH.MDH021	1) History specify A200	(CTN0027CDD:t_frMDH.MDH021s)
	Comments	A200	(C	TN0027CDD: t_frMDH.MDH022)	
* 1	tom is not required				

CDD: CTN0027CDD		Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
MDH001	NUMERIC	
MDH001s	STRING(200) - A200	
VISITDT	DATE - DDMONYYYY	
MDH006	NUMERIC	
MDH006s	STRING(200) - A200	
MDH007	NUMERIC	
MDH007s	STRING(200) - A200	
MDH008	NUMERIC	
MDH009	NUMERIC	
MDH009s	STRING(200) - A200	
MDH010	NUMERIC	
MDH008s	STRING(200) - A200	
MDH012	NUMERIC	
MDH012s	STRING(200) - A200	
MDH013	NUMERIC	
MDH013s	STRING(200) - A200	
MDH014	NUMERIC	
MDH014s	STRING(200) - A200	
MDH015	NUMERIC	
MDH015s	STRING(200) - A200	
MDH016	NUMERIC	
MDH002	NUMERIC	
MDH002s	STRING(200) - A200	

Annotated Trial Design Page 18 of 68

MDH004	NUMERIC	
MDH004s	STRING(200) - A200	
MDH005	NUMERIC	
MDH005s	STRING(200) - A200	
MDH003	NUMERIC	
MDH003s	STRING(200) - A200	
MDH011As	STRING(200) - A200	
MDH011B	NUMERIC	
MDH011Bs	STRING(200) - A200	
MDH010s	STRING(200) - A200	
MDH022	STRING(200) - A200	
MDH016s	STRING(200) - A200	
MDH017	NUMERIC	
MDH017s	STRING(200) - A200	
MDH018	STRING(200) - A200	
MDH018s	STRING(200) - A200	
MDH019	STRING(200) - A200	
MDH019s	STRING(200) - A200	
MDH020	STRING(200) - A200	
MDH020s	STRING(200) - A200	
MDH021	STRING(200) - A200	
MDH021s	STRING(200) - A200	
MDH011A	NUMERIC	

Annotated Trial Design Page 19 of 68

ctn	0027 : Physical Exam (PEX)			
1.	Assessment Date	Req / Req / Req (2006-2010) (CT	FN0027CDD: t_frPEX.VISITDT)	
2.	1. General Appearance	Evaluation Pulldown List 1 (CTN0027CDD:t_frPEX.PEX.0	Comments for Abnormal Results	(CTN0027CDD: t_frPEX.PEX001b)
		Pulldown List 1 (CTN0027CDD: L_ITPEX.PEXC	A200	
3.	2. Head/Neck	Pulldown List 2 CTN0027CDD: t_frPEX.PEX.	002a) A200	(CTN0027CDD:t_frPEX.PEX002b)
4.	3. Ears, Eyes, Nose and Throat	Pulldown List 3 (CTN0027CDD:t_frPEX.PEX0	003a) A200	(CTN0027CDD:t_frPEX.PEX003b)
5.	4. Cardiovascular	Pulldown List 4 (CTN0027CDD:t_frPEX.PEX0	7230	(CTN0027CDD:t_frPEX.PEX004b)
6.	5. Lymph Nodes	Pulldown List 5 (CTN0027CDD: t_frPEX.PEX.	A200	(CTN0027CDD:t_frPEX.PEX005b)
7.	6. Respiratory	Pulldown List 6 (CTN0027CDD: t_frPEX.PEX.	7230	(CTN0027CDD:t_frPEX.PEX006b)
8.	7. Musculoskeletal	Pulldown List 7 (CTN0027CDD:t_frPEX.PEX.	007a) A200	(CTN0027CDD:t_frPEX.PEX007b)
9.	8. Gastrointestinal and Abdomen	Pulldown List 8 (CTN0027CDD:t_frPEX.PEX.	A200	(CTN0027CDD:t_frPEX.PEX008b)
10.	9. Extremities	Pulldown List 9 (CTN0027CDD:t_frPEX.PEX.	009a) A200	(CTN0027CDD:t_frPEX.PEX009b)
11.	10. Neurological	Pulldown List 10 (CTN0027CDD: t_frPEX.PEX	(010a) A200	(CTN0027CDD: t_frPEX.PEX010b)
12.	11. Skin	Pulldown List 11 (CTN0027CDD:t_frPEX.PEX	(011a) A200	(CTN0027CDD:t_frPEX.PEX011b)
13.*	12. Other	Pulldown List 12 (CTN0027CDD: t_frPEX.PEX		
		Specify: A200	(CTN0027CDD: t_frPEX.PEX012b)	
			(CTN0027CDD: t_frPEX.PEX012c)	
		A200	(5.11502.7555.1 <u></u> 11.2.1.1.2.10120)	
* 1	em is not required			

Pulldown List 1:							
RefName	Display Text	Value	Design Note				
ie1Norma	1 Normal	1					
ie2Abnor	2 Abnormal	2					
ie9NtDon	9 Not Done	9					

Pulldown List 2:							
RefName	Display Text	Value	Design Note				
ie1Norma	1 Normal	1					
ie2Abnor	2 Abnormal	2					
ie9NtDon	9 Not Done	9					

Pulldown List 3:						
RefName	Display Text	Value	Design Note			
ie1Norma	1 Normal	1				
ie2Abnor	2 Abnormal	2				
ie9NtDon	9 Not Done	9				

RefName	Display Text	Value	Design Note
ie1Norma	1 Normal	1	
ie2Abnor	2 Abnormal	2	
ie9NtDon	9 Not Done	9	

Pulldown List 5:			
RefName	Display Text	Value	Design Note
ie1Norma	1 Normal	1	
ie2Abnor	2 Abnormal	2	
ie9NtDon	9 Not Done	9	

Pulldown List 6:			
RefName	Display Text	Value	Design Note
ie1Norma	1 Normal	1	
ie2Abnor	2 Abnormal	2	
ie9NtDon	9 Not Done	9	

Pulldown List 7:				
RefName	Display Text	Value	Design Note	
ie1Norma	1 Normal	1		

Annotated Trial Design Page 20 of 68

ie2Abnor	2 Abnormal	2	
ie9NtDon	9 Not Done	9	

Pulldown List 8:			
RefName	Display Text	Value	Design Note
ie1Norma	1 Normal	1	
ie2Abnor	2 Abnormal	2	
ie9NtDon	9 Not Done	9	

Pulldown List 9:			
RefName	Display Text	Value	Design Note
ie1Norma	1 Normal	1	
ie2Abnor	2 Abnormal	2	
ie9NtDon	9 Not Done	9	

Pulldown List 10:			
RefName	Display Text	Value	Design Note
ie1Norma	1 Normal	1	
ie2Abnor	2 Abnormal	2	
ie9NtDon	9 Not Done	9	

Pulldown	List 11:		
RefName	Display Text	Value	Design Note
ie1Norma	1 Normal	1	
ie2Abnor	2 Abnormal	2	
ie9NtDon	9 Not Done	9	

Pulldown List 12:			
RefName	Display Text	Value	Design Note
ie1Norma	1 Normal	1	
ie2Abnor	2 Abnormal	2	
ie9NtDon	9 Not Done	9	

CDD: CTN0027CD	D Table: t_frPEX Key	Type: PATIENTVIS
Column Name	Column Data Type	Design Note
PEX011a	STRING(255) - 1, 2, 9	
PEX011b	STRING(200) - A200	
PEX003b	STRING(200) - A200	
PEX004a	STRING(255) - 1, 2, 9	
PEX004b	STRING(200) - A200	
PEX010b	STRING(200) - A200	
PEX002a	STRING(255) - 1, 2, 9	
VISITDT	DATE - DDMONYYYY	
PEX001a	STRING(255) - 1, 2, 9	
PEX002b	STRING(200) - A200	
PEX003a	STRING(255) - 1, 2, 9	
PEX001b	STRING(200) - A200	
PEX006a	STRING(255) - 1, 2, 9	
PEX007b	STRING(200) - A200	
PEX008a	STRING(255) - 1, 2, 9	
PEX008b	STRING(200) - A200	
PEX009a	STRING(255) - 1, 2, 9	
PEX009b	STRING(200) - A200	
PEX010a	STRING(255) - 1, 2, 9	
PEX012b	STRING(200) - A200	
PEX012c	STRING(200) - A200	
PEX005b	STRING(200) - A200	
PEX006b	STRING(200) - A200	
PEX007a	STRING(255) - 1, 2, 9	
PEX005a	STRING(255) - 1, 2, 9	
PEX012a	STRING(255) - 1, 2, 9	

Annotated Trial Design Page 21 of 68

n0027 : Pregnancy and Birth Control Assessment (PBC) Assessment Date Reg / Reg / Reg / (2006-2010) (CTN0027CDD:t_frPBC_BL.VISITDT)		
issessment Date	Req / Req (2006-2010) (CTN0027CDD: t_frPBC_BL.VISITDT)	
olete this form only for females.		
s participant of childbearing potential?	(CTN0027CDD:L_frPBC_BL.PBC5L) [0]	
ndicate all forms of birth control the participant uses:	(CTN0027CDD:L_frPBC_BL.PBC005A) a Oral Contraceptives:	
	[O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5B) b Barrier (disphragm. cervical cap) with Spermicide, or Condom: [O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5C) c Intrauterine Device (UUD: [O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5D) d Intrauterine Progesterone Contraceptive System (UUD: [O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5D) e Levonorgestre Implant: [O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5F) f Medroxyprogesterone Acatate Contraceptive injection: [O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5F) f Medroxyprogesterone Acatate Contraceptive injection: [O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5F) f Medroxyprogesterone Acatate Contraceptive injection: [O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5F) f Medroxyprogesterone Acatate Contraceptive Injection: [O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5F) I Surgical Sterilization: [O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5F) I Surgical Sterilization: [O] ○ No [1] ○ 1 Yes (CTN0027CDD: LfrPBC_BL_PBCO5F)	
	J Complete Abstinence from Sexual Intercourse: [0] ○ No [1] ○ 1 Yes	
Vas a pregnancy test performed?	(CTN0027CDD:t_frPBC_BL.PBC001) [0] ○ 0 No [1] ○ 1 Yes	
Date of pregnancy test:	Req / Req / Req (2006-2010) (CTN0027CDD:t_frPBC_BL.PBC002)	
regnancy test result:	(CTN0027CDD::_frPBC_BL.PBC003) [1]	
comments:	A200 (CTN0027CDD:t_frPBC_BL.PBC006)	

CDD: CTN0027CDD	Table: t_frPBC_BL	Key Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
PBC005A	NUMERIC	
PBC005B	NUMERIC	
PBC005C	NUMERIC	
PBC005D	NUMERIC	
PBC005E	NUMERIC	
PBC005F	NUMERIC	
PBC005G	NUMERIC	
PBC005H	NUMERIC	
VISITDT	DATE - DDMONYYYY	
PBC5L	NUMERIC	
PBC005I	NUMERIC	
PBC005J	NUMERIC	
PBC001	NUMERIC	
PBC002	DATE - DDMONYYYY	
PBC003	NUMERIC	
PBC003a	NUMERIC	
PBC006	STRING(200) - A200	
		

Annotated Trial Design Page 22 of 68

	n0027 : Risk Behavior Survey (RBS)	
Α.	Drug Use	Is a like a like a control of the co
ļ.	Assessment Date	Req V / Req V / Req V (2006-2010) (CTN0027CDD:t_frRBS0A.VISITDT)
Ris	sk Behaviors Survey	
A.	DRUG USE	
	Have you ever used?	
2.	A 1a. Cocaine by itself (injected or snorted)? (If no use, skip to next drug)	(CTN0027CDD:t_frRBS0A.RBS0A1a) [0] ○ 0 No [1] ○ 1 Yes [9] ○ 9 Unknown [7] ○ 7 Refused
	For text boxes enter: -1 for 'Refused'	b. How many days did you use in the last 30 days? (CTN0027CDD: t_frRBS0A.RBS0A1b)
	-2 for 'Don't Know'	(If 00, -1, -2, do not ask part C-F, and skip to next drug) xx (-2 =< n <= 30)
		c. How many days did you inject _ in the last 30 days? (CTN0027CDD:t_frRBS0A.RBS0A1c)
		(If 00, -1, -2, skip to part e) xx (-2 =< n <= 30)
		d. How many times a day did you inject? (CTN0027CDD:t_frRBS0A.RBS0A1d)
		(Average # of injections/day) xx (-2 = < n <= 99)
		e. How many days did you usewithout injecting (smoking, snorting, swallowing) in the last 30 days? (CTN0027CDD:t_frRBS0A.RBS0A1e) (If 00, -1, -2, then skip to next drug class)
		f. How many times a day did you use without injecting? (CTN0027CDD:t_frRBS0A.RBS0A1f)
		XX (-2 =< n <= 99)
3.	A 2a. Heroin by itself? (If no use, skip to next drug)	(CTN0027CDD:t_frRBS0A.RBS0A2a) [0] ○ 0 No [1] ○ 1 Yes [7] ○ 7 Refused
	For text boxes enter: -1 for 'Refused'	b. How many days did you use in the last 30 days? (If 00, -1, -2, do not ask parts c-f, and skip to next drug) (CTN0027CDD:t_frRBS0A.RBS0A2b)
	-2 for 'Don't Know'	xx (-2 =< n <= 30) c. How many days did you inject in the last 30 days? (CTN0027CDD:t_frRBS0A.RBS0A2c)
		(1f 00, -1, -2, skip to part e)
		xx (-2 =< n <= 30) d. How many times a day did you inject? (CTN0027CDD:t_frRBS0A:RBS0A2d)
		(Average # of injections/day) xx (-2 = < n <= 99)
		e. How many days did you use without injecting (smoking, snorting, swallowing) in the last 30 days? (CTN0027CDD:t_frRBS0A.RBS0A2e)
		(If 00, -1, -2, then skip to next drug class) xx (-2 =< n <= 30)
		f. How many times a day did you use without injecting? (CTN0027CDD:t_frRBS0A.RBS0A2f)
		xx (-2 =< n <= 99)
4.	A 3a. Heroin and cocaine mixed together (Speedball) (If no use, skip to next drug)	(CTN0027CDD:t_frRBS0A.RBS0A3a) [0] ○ 0 No [1] ○ 1 Yes [9] ○ 9 Unknown [7] ○ 7 Refused
	For text boxes enter: -1 for 'Refused'	b. How many days did you use in the last 30 days? (if 00, -1, -2, do not ask parts c-f, and skip to next drug) (CTN0027CDD:1_frRBS0A.RBS0A3b)
	-2 for 'Don't Know'	xx (-2 =< n <= 30) c. How many days did you inject in the last 30 days? (If 00, -1, -2, skip to part e) (CTN0027CDD: t_frRBS0A.RBS0A3c)
		xx (-2 = < n < = 30)
		d. How many times a day did you inject? (CTN0027CDD:t_frRBS0A.RBS0A3d) (Average # of injections/day)
		xx (-2 = < n < = 99)
		e. How many days did you use without injecting (smoking, snorting, swallowing) in the last 30 days? (CTN0027CDD:t_frRBS0A.RBS0A3e) (If 00, -1, -2, then skip to next drug class)
		xx (-2 = < n < = 30)
		f. How many times a day did you usewithout injecting? (CTN0027CDD:t_frRBS0A.RBS0A3f) xx (-2 = < n <= 99)
5.	A 4a. Have you ever used Other Opiates (Demerol, Codeine, Dilaudid)? (If no use, skip to next	(CTN0027CDD:t_frRBS0A.RBS0A4a)
	drug)	[0] 0 No [1] 1 Yes [9] 9 Unknown [7] 7 Refused b. How many days did you use in the last 30 days? (If 00, -1, -2, do not ask parts c-1, and skip to next drug) (CTN0027CDD:t_frRBS0A.RBS0A4b)
	For text boxes enter: -1 for 'Refused'	b. How many days du you use in the last so days: (if 00, -1, -2, do not ask parts c-1, and skip to next drug) (************************************
	-2 for 'Don't Know'	c. How many days did you inject in the last 30 days? (If 00, -1, -2, skip to part e) (CTN0027CDD:t_frRBS0A RBS0A4c)
		xx (-2 =< n <= 30) d. How many times a day did you inject? (CTN0027CDD:t_frRBS0A.RBS0A4d)
		(Average # of injections/day) xx (-2 = < n <= 99)
		e. How many days did you use without injecting (smoking, snorting, swallowing) in the last 30 days? (CTN0027CDD:t_frRBS0A.RBS0A4e)
		(If 00, -1, -2, then skip to next drug class) xx (-2 =< n <= 30)
		f. How many times a day did you use without injecting? (CTN0027CDD:t_frRBS0A.RBS0A4f)
\perp		xx (-2 =< n <= 99)
6.	A 5a. Have you ever used Amphetamines (Speed, Methamphetamine, Crank)? (If no use, skip to next drug)	(CTN0027CDD:t_frRBS0A.RBS0A5a) [0] 0 11 0 1 Yes No Unknown Refused Unknown
	For text boxes enter:	b. How many days did you use in the last 30 days? (If OU, -1, -2, do not ask parts c-1, and skip to next drug) (CHOO270DD CIRCBON.RESON.B)
	-1 for 'Refused' -2 for 'Don't Know'	xx (-2 =< n <= 30) c. How many days did you inject in the last 30 days? (If 00, -1, -2, skip to part e) (CTN0027CDD:t_frRBS0A.RBS0A5c)
		xx (-2 = < n < = 30)
		d. How many times a day did you inject? (Average # of injections/day) (CTN0027CDD:t_frRBS0A.RBS0A5d) xx (-2 = < n <= 99)
		e. How many days did you use without injecting (smoking, snorting, swallowing) in the last 30 days? (If 00, -1, -2, then skip to next drug (CTN0027CDD:t_frRBS0A.RBS0A5e)
		class) xx
		f. How many times a day did you use without injecting? (CTN0027CDD:t_frRBS0A.RBS0A5f)
L		xx (-2 = < n < = 99)
B.	Drug Injection (if no injection use in past 30 days, skip to section C.)	
Fo	r text boxes enter -1 for 'Refused', -2 for 'Don't Know'	
7.	B1. In the last 30 days, how many times (# of injections) did you inject using works	(CTN0027CDD:t_frBS0A.rgR85081)

Annotated Trial Design Page 23 of 68

	(needle/syringes) that you know had been used by somebody else? (If 0, -1, -2, or NA, then select NA for B2)	[1] O xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSOA.RBSOB1) [96] ONA
8.	B2. Of the times you injected after someone, how many times did you clean the works with full-strength bleach?	(CTN0027CDD:_frRBS0A.rgRBS0B2) [1] ○ xxx
9.	B3. How many times in the last 30 days did you use a cooker/cotton /rinse water that had been used by another injector?	(CTN0027CDD:t_frRBS0A.rgRBS0B3) [1] ○ xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBS0A.RBS0B3) [96] ○ NA
10.	B4. How many times in the last 30 days did you fix drugs with another person, then split the drug solution (through use of the same cooker/spoon or through front or back loading)?	(CTN0027CDD:t_frRBS0A.rgRBS0B4) [1]
C. 9	exual Activity	
For	text boxes enter -1 for 'Refused', -2 for 'Don't Know'	
11.	C1. During the last 30 days, with how many people did you have vaginal, oral or anal sex?(IF NONE, ENTER 000, AND THE QUESTIONNAIRE IS COMPLETED)	(CTN0027CDD:_frRBS0A.rgRBS0C1) [1] ○ xxx
12.		(CTN0027CDD:t_frRBS0A:rgRBS0C2) [1] ○ xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBS0A:RBS0C2) [96] ○ NA
13.	C3. How many of your partners were male? (Number cannot exceed total number of people (qC1))	(CTN0027CDD:t_frRBS0A:rgRBS0C3) [1] ○ xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBS0A:RBS0C3) [96] ○ NA
14.	C4.Interviewer: Code gender of respondent. After submission of this form, please complete relevant form (either RBSMale, RBSFemale, or RBSAII).	(CTN0027CDD:t_frRBS0A RBS0C4) [1] ① 1 Male [2] ② 2 Female [9] ③ 9 Don't know [96] ③ NA
*	tem is not required	

Item Des	tem Design Notes:		
Item No.	Design Note		
14.	If Male and item 10 is >0, then dynamically create RBSMale, if female and item 10 is >0, then dynamically create RBS2Female, if Don't Know and item 10 is >0, then dynamically create RBS2All		

CDD: CTN0027CDD	Table: t_frRBS0A	Key Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
RBS0A2f	NUMERIC - N2	
RBS0A3a	NUMERIC	
rgRBS0C2	NUMERIC	
RBS0C2	NUMERIC - N3	
rgRBS0C3	NUMERIC	
RBS0C3	NUMERIC - N3	
RBS0C4	NUMERIC	
RBS0A3b	NUMERIC - N2	
RBS0A3c	NUMERIC - N2	
RBS0A3d	NUMERIC - N2	
RBS0A3e	NUMERIC - N2	
RBS0A3f	NUMERIC - N2	
RBS0A4a	NUMERIC	
RBS0A4b	NUMERIC - N2	
RBS0A4c	NUMERIC - N2	
RBS0A4d	NUMERIC - N2	
RBS0A4e	NUMERIC - N2	
RBS0A4f	NUMERIC - N2	
RBS0A5a	NUMERIC	
RBS0A5d	NUMERIC - N2	
RBS0A5e	NUMERIC - N2	
RBS0A5f	NUMERIC - N2	
gRBS0B1	NUMERIC	
RBS0B1	NUMERIC - N3	
gRBS0B2	NUMERIC	
RBS0B2	NUMERIC - N3	
gRBS0B3	NUMERIC	
RBS0B3	NUMERIC - N3	
gRBS0B4	NUMERIC	
RBS0B4	NUMERIC - N3	
rgRBS0C1	NUMERIC	
RBS0C1	NUMERIC - N3	
RBS0A5b	NUMERIC - N2	
RBS0A5c	NUMERIC - N2	
RBS0A2e	NUMERIC - N2	
RBS0A2b	NUMERIC - N2	
RBS0A2c	NUMERIC - N2	
RBS0A2d	NUMERIC - N2	
VISITDT	DATE - DDMONYYYY	
RBS0A1a	NUMERIC	
RBS0A1b	NUMERIC - N2	
RBS0A1c	NUMERIC - N2	

Annotated Trial Design Page 24 of 68

RBS0A1d	NUMERIC - N2	
RBS0A1e	NUMERIC - N2	
RBS0A1f	NUMERIC - N2	
RBS0A2a	NUMERIC	

Annotated Trial Design Page 25 of 68

ctn0027 : RISK BEHAVIORS SURVEY (2 of 2) (RBSMale)				
1. Assessment Date				
D. Ask Male/Female Clients who had Female Partners				
For text boxes enter -1 for 'Refused', -2 for 'Don't Know'				
2. D 1a. How many women performed oral sex ("went down") on you? (If 0, then enter NA for 1b and 1c . Number cannot exceed total number of female partners	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSM.RBS0D1a)			
(qc2))	b. How often did your partner(s) perform oral sex ('go down') on you?			
	Pulldown List 1			
	Pulldown List 2 (CTN0027CDD: LfrRSM.RSS0D1c)			
3. D 2a. How many women did you perform oral sex ("go down") on? (If 0, then enter NA for 2b and 2c. Number cannot exceed total number of female partners	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSM.RBS0D2a)			
(qC2))	b. How often did you perform oral sex ('go down') on your partner(s)? Pulldown List 3 (CTN0027CDD:L_frRBSM.RBS0D2b)			
	Pulldown List 3 (CTN0027CDD:t_frRBSM.RBS0D2b) c. How often did you use condoms/dental dams when you performed oral sex ('went down') on your partner(s)?			
	Pulldown List 4 (CTN0027CDD: t_frRBSM.RBS0D2c)			
E. Ask Male Clients who had Female Partners:				
For text boxes enter -1 for 'Refused', -2 for 'Don't Know'				
4. E 1a. How many women did you have vaginal sex with? (If 0, then enter NA for 1b and 1c . Number cannot exceed total number of female partners (qC2))	xxx			
	b. How often did you have vaginal sex? Pulldown List [v] (CTNOQCTOD: L_fRBSM.RBS0E1b)			
	c. How often did you use a condom?			
	Pulldown List 6 CTN0027CDD:L_frRBSM.RBS0E1c)			
5. E 2a. How many women did you have (insertive) anal with? (If 0, then enter NA for 2b and 2c. Number cannot exceed total number of female partners (q2C)).	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSM.RBS0E2a)			
	b. How often did you have (insertive) anal sex?			
	c. How often did you use a condom?			
	Pulldown List 8 CTN0027CDD: t_frRBSM.RBS0E2c)			
F. Ask Male Clients who had Male Partners:				
For text boxes enter -1 for 'Refused', -2 for 'Don't Know'				
6. F 1a. How many men did you have (insertive) anal sex with? (If 0, then enter NA for 1b and 1c. Number cannot exceed total number of male partners (qC3)).	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSM.RBS0F1a)			
	b. How often did you have (insertive) anal sex?			
	Pulldown List 9 V (CTN0027CDD:t_frRBSM.RBS0F1b) c. How often did you use condom?			
	Pulldown List 10 (CTN0027CDD:t_frRBSM.RBS0F1c)			
G. Ask Male/Female Clients who had Male Partners				
For text boxes enter -1 for 'Refused', -2 for 'Don't Know'				
7. G 1a. How many men performed oral sex ("went down") on you? (If 0, then enter NA for 1b and 1c. Number cannot exceed total number of male partners)	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSM.RBSOG1a)			
	b. How often did your partner(s) perform oral sex ('go down') on you? Pulldown List 11 (CTN0027CDD: t_frRBSM.RBS0G1b)			
	Pulldown List 11 v			
	Pulldown List 12 V (CTN0027CDD:t_frRBSM.RBS0G1c)			
8. G 2a. How many men did you perform oral sex ("go down") on? (If 0, then enter NA for 2b and 2c. Number cannot exceed total number of male partners (qC3))	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSM.RBS0G2a)			
(dos))	b. How often did you perform oral sex ("go down") on your partner(s)? Pulldown List 13 ("KN002/CDD: [FRBSM.RBS0G2b)			
	Pulladwil List 13			
	Pulldown List 14 (CTN0027CDD:t_frRBSM.RBS0G2c)			
I. Ask Male/Female Clients who had Male Partners				
For text boxes enter -1 for 'Refused', -2 for 'Don't Know'				
9. I 1a. How many men did you have (receptive) anal sex with? (If 0, then enter NA for 1b and 1c. Number cannot exceed total number of male partners(qC3)	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSM.RBS011a)			
	b. How often did you have (receptive) anal sex? Pulldown List 15 (CTN0027CDD:t_frRBSM.RBS0I1b)			
	Pulldown List 15 \(\times \) (C \(\times \) (C \(\times \) (C \(\times \) (C \\ \times \) (T \(\times \) (T \\ \times \) (S \(\times \) (T \\ \times \) (S \(\times \) (T \\ \times \) (S \(\times \)			
	Dulldown List 14 (CTN0027CDD:t frPRSM PRS011c)			

Form Design Note:

created by 'Male' on RBS1

Pulldown List 1:				
RefName	Display Text	Value	Design Note	
ieSexFr1	1 Once or irregularly	1		
ieSexFr2	2 Less than once a week	2		
ieSexFr3	3 About once a week	3		
ieSexFr4	4 2-6 times a week	4		
ieSexFr5	5 About once a day	5		
ieSexFr6	6 2-3 times a day	6		
ieSexFr7	7 4 or more times a day	7		
ieSexFr8	99 Don't know/unsure	99		
ieSexFr9	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 2:			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	

Annotated Trial Design Page 26 of 68

ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 3:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

andown List 4.			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 5:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 6:

RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 7:

Pulldown List 7:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

V-l	
value	Design Note
0	
	0

Annotated Trial Design Page 27 of 68

ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 9:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 10:			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 11:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 12:			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 13:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 14:			
RefName	Display Text	Value	Design Note

Annotated Trial Design Page 28 of 68

I	ii i	1	ı
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 15:				
RefName	Display Text	Value	Design Note	
ieSexFr1	1 Once or irregularly	1		
ieSexFr2	2 Less than once a week	2		
ieSexFr3	3 About once a week	3		
ieSexFr4	4 2-6 times a week	4		
ieSexFr5	5 About once a day	5		
ieSexFr6	6 2-3 times a day	6		
ieSexFr7	7 4 or more times a day	7		
ieSexFr8	99 Don't know/unsure	99		
ieSexFr9	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 16:				
RefName	Display Text	Value	Design Note	
ieSexCo1	0 Never	0		
ieSexCo2	1 Less than half the time	1		
ieSexCo3	2 About half the time	2		
ieSexCo4	3 More than half the time	3		
ieSexCo5	4 Always	4		
ieSexCo6	99 Don't know/unsure	99		
ieSexCo7	77 Refused	77		
ieRBS_NA	96 NA	96		

CDD: CTN0027CDD Table: t_frRBSM Key Type: PATIENTVISIT		
Column Name	Column Data Type	Design Note
RBS0D1a	NUMERIC - N3	
RBS0D1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0D1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0D2a	NUMERIC - N3	
VISITDT	DATE - DDMONYYYY	
RBS0G1a	NUMERIC - N3	
RBS0G1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0G1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0D2b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0D2c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0E1a	NUMERIC - N3	
RBS0E1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0E1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0E2a	NUMERIC - N3	
RBS0E2b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0E2c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0F1a	NUMERIC - N3	
RBS0F1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0F1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0I1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0G2c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0I1a	NUMERIC - N3	
RBS0I1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0G2a	NUMERIC - N3	
RBS0G2b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	

Annotated Trial Design Page 29 of 68

ctn0027 : Risk Behaviors Surveys (2 of 2) (RBSFemale)	
1. Assessment Date	Req / Req / Req (2006-2010) (CTN0027CDD:t_frRBSF.VISITDT)
D. Ask Male/Female Clients who had Female Partners	
For text boxes enter -1 for 'Refused', -2 for 'Don't Know'	
2. D 1a. How many women performed oral sex ("went down") on you? (If 0, then enter NA for 1b and 1c . Number cannot exceed total number of female partner	s xxx (-2 = < n <= 999) (CTN0027CDD:t_fr8BSF.RBS0D1a)
(qC2))	b. How often did your partner(s) perform oral sex ('go down') on you? Pulldown List 1 (CTN0027CDD:t_frRBSF.RBS0D1b)
	C. How offen did you use condoms/dental dams when your partner(s) perform oral sex ('went down') on you?
	Pulldown List 2 (CTN0027CDD: t_frRBSF.RBSOD1c)
3. D 2a. How many women did you perform oral sex ("go down") on? (If 0, then enter NA for 2b and 2c . Number cannot exceed total number of female partners (qc2))	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSF.RBS0D2a)
(qcz))	b. How often did you perform oral sex ('go down') on your partner(s)? Pulldown List 3 w
	c. How often did you use condoms/dental dams when you performed oral sex ('went down') on your partner(s)?
	Pulldown List 4 (CTN0027CDD:t_frRBSF.RBS0D2c)
G. Ask Male/Female Clients who had Male Partners	
For text boxes enter -1 for 'Refused', -2 for 'Don't Know'	
4. G 1a. How many men performed oral sex ("went down") on you? (If 0, then enter NA for 1b and 1c. Number cannot exceed total number of male partners)	xxx
	b. How often did your partner(s) perform oral sex ('go down') on you? Pulldown List 5 (CTN0027CDD:t_frRBSF.RBS0G1b)
	C. How offen did you use condoms/dental dams when your partner(s) performed oral sex ('went down') on you?
	Pulldown List 6 (CTN0027CDD:t_frRBSF.RBS0G1c)
5. G 2a. How many men did you perform oral sex ("go down") on? (If 0, then enter NA for 2b and 2c. Number cannot exceed total number of male partners	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSF.RBS0G2a)
(qC3))	b. How often did you perform oral sex ('go down') on your partner(s)? Pulldown List 7 (CTN0027CDD:t_frRBSF.RBS0G2b)
	Pulldown List 7 (CTN0027CDD: t_frRBSF.RBS0G2b) c. How often did you use condoms/dental dams when you performed oral sex ('went down') on your partner(s)?
	Pulldown List 8 (CTN0027CDD: t_frRBSF.RBS0G2c)
H. Ask Female Clients who had Male Partners:	
For text boxes enter -1 for 'Refused', -2 for 'Don't Know'	
6. H 1a. How many men did you have vaginal sex with? (If 0, then enter NA for 1b and 1c. Number cannot exceed total number of male partners (qC3)).	xxx (-2 =< n <= 999) (CTN0027CDD:LfrRBSF.RBS0H1a)
	b. How often did you have vaginal sex?
	Pulldown List 9 ✓ (CTN0027CDD:t_frRBSF.RBS0H1b) c. How often did you use a condom?
	Pulldown List 10 (CTN0027CDD: t_frRBSF.RBS0H1c)
L Ask Male/Female Clients who had Male Partners	
7. I 1a. How many men did you have (receptive) anal sex with? (If 0, then enter NA for 1b and 1c. Number cannot exceed total number of male partners(qC3)	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBSF.RBS0I1a)
	b. How often did you have (receptive) anal sex?
	Pulldown List 11 V (CTN0027CDD:t_frRBSF.RBS011b) c. How often did you use a condom?
	c. No stell uit you doe a company. Pulldown List 12 V (CTN0027CDD::_frRBSF.RBS011c)

Form Design Note:

created by 'Female' on RBS1

Pulldown List 1:				
RefName	Display Text	Value	Design Note	
ieSexFr1	1 Once or irregularly	1		
ieSexFr2	2 Less than once a week	2		
ieSexFr3	3 About once a week	3		
ieSexFr4	4 2-6 times a week	4		
ieSexFr5	5 About once a day	5		
ieSexFr6	6 2-3 times a day	6		
ieSexFr7	7 4 or more times a day	7		
ieSexFr8	99 Don't know/unsure	99		
ieSexFr9	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 2:			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 3:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	

Annotated Trial Design Page 30 of 68

ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 4:				
RefName	Display Text	Value	Design Note	
ieSexCo1	0 Never	0		
ieSexCo2	1 Less than half the time	1		
ieSexCo3	2 About half the time	2		
ieSexCo4	3 More than half the time	3		
ieSexCo5	4 Always	4		
ieSexCo6	99 Don't know/unsure	99		
ieSexCo7	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 5:				
RefName	Display Text	Value	Design Note	
ieSexFr1	1 Once or irregularly	1		
ieSexFr2	2 Less than once a week	2		
ieSexFr3	3 About once a week	3		
ieSexFr4	4 2-6 times a week	4		
ieSexFr5	5 About once a day	5		
ieSexFr6	6 2-3 times a day	6		
ieSexFr7	7 4 or more times a day	7		
ieSexFr8	99 Don't know/unsure	99		
ieSexFr9	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 6:				
RefName	Display Text	Value	Design Note	
ieSexCo1	0 Never	0		
ieSexCo2	1 Less than half the time	1		
ieSexCo3	2 About half the time	2		
ieSexCo4	3 More than half the time	3		
ieSexCo5	4 Always	4		
ieSexCo6	99 Don't know/unsure	99		
ieSexCo7	77 Refused	77		
ieRBS_NA	96 NA	96		
icitaba_itit	70 101	,,,		

Pulldown List 7:				
RefName	Display Text	Value	Design Note	
ieSexFr1	1 Once or irregularly	1		
ieSexFr2	2 Less than once a week	2		
ieSexFr3	3 About once a week	3		
ieSexFr4	4 2-6 times a week	4		
ieSexFr5	5 About once a day	5		
ieSexFr6	6 2-3 times a day	6		
ieSexFr7	7 4 or more times a day	7		
ieSexFr8	99 Don't know/unsure	99		
ieSexFr9	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 8:			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 9:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	

Annotated Trial Design Page 31 of 68

ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 10:				
RefName	Display Text	Value	Design Note	
ieSexCo1	0 Never	0		
ieSexCo2	1 Less than half the time	1		
ieSexCo3	2 About half the time	2		
ieSexCo4	3 More than half the time	3		
ieSexCo5	4 Always	4		
ieSexCo6	99 Don't know/unsure	99		
ieSexCo7	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 11:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 12:			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

CDD: CTN00270	CDD Table: t_frRBSF Key Type: PATIEN	TVISIT
Column Name	Column Data Type	Design Note
RBS0G2b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0G2c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0H1a	NUMERIC - N3	
RBS0H1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0H1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0I1a	NUMERIC - N3	
RBS0I1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0I1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0G1a	NUMERIC - N3	
RBS0G1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0G1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
VISITDT	DATE - DDMONYYYY	
RBS0D1a	NUMERIC - N3	
RBS0D1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0D1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0D2a	NUMERIC - N3	
RBS0D2b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0D2c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0G2a	NUMERIC - N3	

Annotated Trial Design Page 32 of 68

ctr	n0027 : Risk Behavior Surveys (2 of 2) (RBSAII)				
1.	Assessment Date	Req 💟 / Req 💟 / Req 💟 (2006-2010) (CTN0027CDD:t_frRBS2All.VISITDT)			
D. A	Ask Male/Female Clients who had Female Partners				
For	text boxes enter -1 for 'Refused', -2 for 'Don't Know'				
2.	D 1a. How many women performed oral sex ("went down") on you? (If 0, then enter NA for 1b and 1c . Number cannot exceed total number of female partners (qC2))	$\left \begin{array}{ll} xxx & \left(-2 = < \ n < = \ 999 \right) \left \begin{array}{ll} (CTN0027CDD: L_f RBS2All.RBS0D1a) \end{array} \right.$			
	remare partiers (402))	b. How often did your partner(s) perform oral sex ('go down') on you?			
		c. How often did you use condoms/dental dams when your partner(s) perform oral sex ('went down') on you?			
_					
3.	D 2a. How many women did you perform oral sex ("go down") on? (If 0, then enter NA for 2b and 2c . Number cannot exceed total number of female partners(qC2))	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBS2All.RBS0D2a) b. How often did you perform oral sex ('go down') on your partner(s)?			
		Pulldown List 3 (CTN0027CDD:t_frRBS2All.RBS0D2b)			
		c. How often did you use condoms/dental dams when you performed oral sex ('went down') on your partner(s)? Pulldown List 4 (CTN0027CDD:1_frRBS2AII.RBS0D2c)			
E. /	Ask Male Clients who had Female Partners:				
For	text boxes enter -1 for 'Refused', -2 for 'Don't Know'				
4.	E 1a. How many women did you have vaginal sex with? (If 0, then enter NA for 1b and 1c . Number cannot exceed total number of female partners (gC2))	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBS2All.RBS0E1a)			
	partners (4027)	b. How often did you have vaginal sex? Pulldown List 5 (CTN0027CDD:t_frRBS2All.RBS0E1b)			
		c. How often did you use a condom?			
		Pulldown List 6 (CTN0027CDD:t_frRBS2All.RBS0E1c)			
5.	E 2a. How many women did you have (insertive) anal with? (If 0, then enter NA for 2b and 2c. Number cannot exceed total number of female partners (q2C)).	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBS2All.RBS0E2a) b. How often did you have (insertive) anal sex?			
		Pulldown List 7 🔽 (CTN0027CDD: t_frRBS2All.RBS0E2b)			
		c. How often did_you use a condom?			
F. A	F. Ask Male Clients who had Male Partners:				
For	text boxes enter -1 for 'Refused', -2 for 'Don't Know'				
6.	F 1a. How many men did you have (insertive) anal sex with? (If 0, then enter NA for 1b and 1c. Number cannot exceed total number of male	xxx			
	partners (qC3)).	b. How often did you have (insertive) anal sex? Pulldown List 9 (CTN0027CDD:t_frRBS2All.RBS0F1b)			
		c. How often did you use condom?			
L	Ask Male/Female Clients who had Male Partners	Pulldown List 10 (CTN0027CDD:t_frRBS2All.RBS0F1c)			
-	text boxes enter -1 for 'Refused', -2 for 'Don't Know' G 1a. How many men performed oral sex ("went down") on you? (If 0, then enter NA for 1b and 1c. Number cannot exceed total number of	xxx			
	male partners)	b. How often did your partner(s) perform oral sex ('go down') on you?			
		Pulldown List 11 V (CTN0027CDD:t_frRBS2All.RBS0G1b)			
		c. How often did you use condoms/dental dams when your partner(s) performed oral sex ('went down') on you? Pulldown List 12 CTN0027CDD: t_frRBS2All.RBS0G1c)			
8.	G 2a. How many men did you perform oral sex ("go down") on? (If 0, then enter NA for 2b and 2c. Number cannot exceed total number of male	XXX			
	partners (qC3))	b. How often did you perform oral sex ('go down') on your partner(s)? Pulldown List 13 V (CTN0027CDD:t_frRBS2All.RBS0G2b)			
		c. How often did you use condoms/dental dams when you performed oral sex ('went down') on your partner(s)?			
		Pulldown List 14 (CTN0027CDD: _frRBS2All RBS0G2c)			
	Ask Female Clients who had Male Partners:				
-	text boxes enter -1 for 'Refused', -2 for 'Don't Know'	LODGE AND A CONTROL OF THE CONTROL O			
9.	H 1a. How many men did you have vaginal sex with? (If 0, then enter NA for 1b and 1c. Number cannot exceed total number of male partners (qC3)).	xxx (-2 =< n <= 999) (CTN0027CDD:t_frRBS2All.RBS0H1a) b. How often did you have vaginal sex?			
		Pulldown List 15 V (CTN0027CDD:t_frRBS2All.RBS0H1b)			
		c. How often did you use a condom? Pulldown List 16 (CTN0027CDD:t_frRBS2All.RBS0H1c)			
I. A	l sk Male/Female Clients who had Male Partners				
For	text boxes enter -1 for 'Refused', -2 for 'Don't Know'				
10.	I 1a. How many men did you have (receptive) anal sex with? (If 0, then enter NA for 1b and 1c. Number cannot exceed total number of male partners(qC3)	XXX (-2 =< n <= 999) (CTN0027CDD:_fr\(\text{RBS2AII.RBS011a}\)			
	parties 3(403)	b. How often did you have (receptive) anal sex? Pulldown List 17 (CTN0027CDD:t_frRBS2All.RBS0I1b)			
		c. How often did you use a condom?			
		Rulldown List 18 CTN0027CDD:t_frRBS2AII.rBS011c)			

Pulldown List 1:				
RefName	Display Text	Value	Design Note	
ieSexFr1	1 Once or irregularly	1		
ieSexFr2	2 Less than once a week	2		
ieSexFr3	3 About once a week	3		
ieSexFr4	4 2-6 times a week	4		
ieSexFr5	5 About once a day	5		
ieSexFr6	6 2-3 times a day	6		
ieSexFr7	7 4 or more times a day	7		
ieSexFr8	99 Don't know/unsure	99		
ieSexFr9	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 2:			

Annotated Trial Design Page 33 of 68

1		i
Display Text	Value	Design Note
0 Never	0	
1 Less than half the time	1	
2 About half the time	2	
3 More than half the time	3	
4 Always	4	
99 Don't know/unsure	99	
77 Refused	77	
96 NA	96	
	1 Less than half the time 2 About half the time 3 More than half the time 4 Always 99 Don't know/unsure 77 Refused	0 Never 0 1 Less than half the time 1 2 About half the time 2 3 More than half the time 3 4 Always 4 99 Don't know/unsure 99 77 Refused 77

Pulldown List 3:				
RefName	Display Text	Value	Design Note	
ieSexFr1	1 Once or irregularly	1		
ieSexFr2	2 Less than once a week	2		
ieSexFr3	3 About once a week	3		
ieSexFr4	4 2-6 times a week	4		
ieSexFr5	5 About once a day	5		
ieSexFr6	6 2-3 times a day	6		
ieSexFr7	7 4 or more times a day	7		
ieSexFr8	99 Don't know/unsure	99		
ieSexFr9	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 4:				
Display Text	Value	Design Note		
0 Never	0			
1 Less than half the time	1			
2 About half the time	2			
3 More than half the time	3			
4 Always	4			
99 Don't know/unsure	99			
77 Refused	77			
96 NA	96			
	0 Never 1 Less than half the time 2 About half the time 3 More than half the time 4 Always 99 Don't know/unsure 77 Refused	0 Never 0 1 Less than half the time 1 2 About half the time 2 3 More than half the time 3 4 Always 4 99 Don't know/unsure 99 77 Refused 77		

Pulldown List 5:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 6:			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 7:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Annotated Trial Design Page 34 of 68

Pulldown List 8:				
RefName	Display Text	Value	Design Note	
ieSexCo1	0 Never	0		
ieSexCo2	1 Less than half the time	1		
ieSexCo3	2 About half the time	2		
ieSexCo4	3 More than half the time	3		
ieSexCo5	4 Always	4		
ieSexCo6	99 Don't know/unsure	99		
ieSexCo7	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 9:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 10:			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 11:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 12:			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 13:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Annotated Trial Design Page 35 of 68

Pulldown	Pulldown List 14:			
RefName	Display Text	Value	Design Note	
ieSexCo1	0 Never	0		
ieSexCo2	1 Less than half the time	1		
ieSexCo3	2 About half the time	2		
ieSexCo4	3 More than half the time	3		
ieSexCo5	4 Always	4		
ieSexCo6	99 Don't know/unsure	99		
ieSexCo7	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 15:			
RefName	Display Text	Value	Design Note
ieSexFr1	1 Once or irregularly	1	
ieSexFr2	2 Less than once a week	2	
ieSexFr3	3 About once a week	3	
ieSexFr4	4 2-6 times a week	4	
ieSexFr5	5 About once a day	5	
ieSexFr6	6 2-3 times a day	6	
ieSexFr7	7 4 or more times a day	7	
ieSexFr8	99 Don't know/unsure	99	
ieSexFr9	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 16:			
RefName	Display Text	Value	Design Note
ieSexCo1	0 Never	0	
ieSexCo2	1 Less than half the time	1	
ieSexCo3	2 About half the time	2	
ieSexCo4	3 More than half the time	3	
ieSexCo5	4 Always	4	
ieSexCo6	99 Don't know/unsure	99	
ieSexCo7	77 Refused	77	
ieRBS_NA	96 NA	96	

Pulldown List 17:				
RefName	Display Text	Value	Design Note	
ieSexFr1	1 Once or irregularly	1		
ieSexFr2	2 Less than once a week	2		
ieSexFr3	3 About once a week	3		
ieSexFr4	4 2-6 times a week	4		
ieSexFr5	5 About once a day	5		
ieSexFr6	6 2-3 times a day	6		
ieSexFr7	7 4 or more times a day	7		
ieSexFr8	99 Don't know/unsure	99		
ieSexFr9	77 Refused	77		
ieRBS_NA	96 NA	96		

Pulldown List 18:				
RefName	Display Text	Value	Design Note	
ieSexCo1	0 Never	0		
ieSexCo2	1 Less than half the time	1		
ieSexCo3	2 About half the time	2		
ieSexCo4	3 More than half the time	3		
ieSexCo5	4 Always	4		
ieSexCo6	99 Don't know/unsure	99		
ieSexCo7	77 Refused	77		
ieRBS_NA	96 NA	96		

CDD: CTN0027CDD Table: t_frRBS2All Key Type: PATIENTVISIT				
Column Name	Column Data Type	Design Note		
VISITDT	DATE - DDMONYYYY			
RBS0D2b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96			
RBS0D2c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96			
RBS0E1a	NUMERIC - N3			
RBS0D1a	NUMERIC - N3			
RBS0D1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96			
RBS0D1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96			
RBS0D2a	NUMERIC - N3			
RBS0H1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96			

Annotated Trial Design Page 36 of 68

RBS0H1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	1
RBS0I1a	NUMERIC - N3	
RBS0I1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0I1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0H1a	NUMERIC - N3	
RBS0F1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0F1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0G1a	NUMERIC - N3	
RBS0G1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0G1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0G2a	NUMERIC - N3	
RBS0G2b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0E1b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0E1c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0E2a	NUMERIC - N3	
RBS0E2b	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 99, 77, 96	
RBS0E2c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	
RBS0F1a	NUMERIC - N3	
RBS0G2c	STRING(255) - 0, 1, 2, 3, 4, 99, 77, 96	

Annotated Trial Design Page 37 of 68

n0027 : Substance Use (TFB-Lead)					
1. Assessment Date [editable]	Req V / Req V / Req V (2006-2010) (CTN0027CDD:t_frDRG.VISITDT / Assessment Date)				
Have any illicit substances or alcohol been taken within the date range specified below? If Yes, please complete TFB form for this visit.	(CTN0027CDD:L_frDRG.DRG) [0]				
3. Start Date:	NReq V / NReq V / NReq V (2006-2010) (CTN0027CDD:t_frDRG.DRGSTART / TFB Start Date)				
4. Stop Date: Please confirm that each day of the assessment period has been reviewed with the participant.	NReq / NReq / NReq (2006-2010) (CTN0027CDD:t_frDRG.DRGSTOP / TFB Stop Date)				

CDD: CTN0027CDD	Table: t_frDRG K	ey Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
DRG	NUMERIC	
VISITDT	DATE - DDMONYYYY	
DRGSTART	DATE - DDMONYYYY	
DRGSTOP	DATE - DDMONYYYY	

Annotated Trial Design Page 38 of 68

ctn	0027 : Tim	ne Line	Follow	BackA	Active Stu	dy (TFB) -	Repea	ting Form														
#	Substance Use Date				Cannaboids taken?	Cannaboids Route	Cocaine taken?	Cocaine Amphet	amine Amphetamine Route	Methamphetamine taken?	Methamphetamine Route	Opiates taken?	Opiates Route	Benzodiazepines taken?	Benzodiazepines Route	Propoxyphene taken?	Propoxyphene Route	Methadone taken?	Methadone Route	Oxycodone taken?	Other taken?	Other Route
1 0																						

Tim	e Line Follow Back-Active Study	
1.	Substance Use Date:	Req V / Req V / Req W (2006-2010) (CTN0027CDD:t_fTFB.TFB001)
2.	1. Alcohol:	(CTN0027CDD::_frFB.FFB001A) Was substance taken? [0] ○ 0 No [1] ○ 1 Yes
3.*	Alcohol Quantity	A50 (CTN0027CDD:t_frTFB.TFB001B)
4.*	Route	Pulldown List 1 V (CTN0027CDD:t_frFB.TFB001C)
5.	2. Cannabolds:	(CTN0027CDD:_frTFB.TFB002A) Was substance taken? [0] \[\circ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
6.*	Route	Pulldown List 2 V (CTN0027CDD:t_frTFB.TFB002B)
7.	3. Cocaine:	(CTN0027CDD:frTFB.TFB003A) Was substance taken? [O] ○ 0 No [1] ○ 1 Yes
8.*	Route	Pulldown List 3 (CTN0027CDD:t_frTFB.TFB003B)
9.	4. Amphetamine:	(CTN0027CDD:frFB.TFB004A) Was substance taken? [0] ○ 0 No [1] ○ 1 Yes
10.	Route	Pulldown Llst 4 V (CTN0027CDD:t_frTFB.TFB004B)
11.	5. Methamphetamine:	(CTN0027CDD::_frFB.TFB005A) Was substance taken? [0] ○ 0 No [1] ○ 1 Yes
12.	Route	Pulldown Llst 5 V (CTN0027CDD:t_frFB.TFB005B)
13.	6. Opiates:	(CTN0027CDD:t_frFB.TFB006A) Was substance taken? [0] ○ 0 No [1] ○ 1 Yes
14.	Route	Pulldown List 6 ((CTN0027CDD: t_frF8.1F8006B)
15.	7. Benzodiazepines:	(CTN0027CDD::_frFFB.TFB007A) Was substance taken? [O] ○ 0 No [7] ○ 1 Yes
16.	Route	Pulldown Llst 7 V (CTN0027CDD:t_frF8.FF8007B)
17.	8. Propoxyphene:	(CTN0027CDD:t_frTFB.TFB008A) Was substance taken? [0] ○ 0 No [1] ○ 1 Yes
18.	Route	Pulldown Llst 8 (CTN0027CDD:t_frTFB.TFB008B)
19.	9. Methadone:	(CTN0027CDD:t_frFB.TFB009A) Was substance taken? [0] ○ 0 No [1] ○ 1 Yes
20.	Route	Pulldown List 9 (CTN0027CDD:t_frF8.FB0098)
21.	10. Oxycodone:	(CTN0027CDD::[rTFB.TFB010A) Was substance taken? [O] ○ 0 No [1] ○ 1 Yes
22.	Route	Pulldown List 10 V (CTN0027CDD: L*frfFB.TFB010B)
23.	11. Other:	(CTN0027CDD::LfrTFB.TFB011A) Was substance taken? [O] ○ 0 No [1] ○ 1 Yes
24.	Other (specify):	A255 (CTN0027CDD:t_frFFB.TFB011B)
25.	Route	Pulldown List 11 CTN0027CDD:t_frTFB.TFB011C)
*	tem is not required	

Pulldown List 1:					
RefName	Display Text	Value	Design Note		
ie010ral	01 Oral	1			
ie02Nasal	02 Nasal	2			
ie03Inhaled	03 Inhaled	3			
ie04Vein	04 Shot up - vein	4			
ie05Muscle	05 Shot up - muscle	5			
ie06Skin	06 Shot up - skin	6			
ie07Tongue	07 Dissolved under tongue	7			
ie08Topical	08 Topical	8			
ie09Rectal	09 Rectal	9			
ie10Vaginal	10 Vaginal	10			

Pulldown List 2:

Annotated Trial Design Page 39 of 68

RefName	Display Text	Value	Design Note
ie010ral	01 Oral	1	
ie02Nasal	02 Nasal	2	
ie03Inhaled	03 Inhaled	3	
ie04Vein	04 Shot up - vein	4	
ie05Muscle	05 Shot up - muscle	5	
ie06Skin	06 Shot up - skin	6	
ie07Tongue	07 Dissolved under tongue	7	
ie08Topical	08 Topical	8	
ie09Rectal	09 Rectal	9	
ie10Vaginal	10 Vaginal	10	

Pulldown List 3:				
RefName	Display Text	Value	Design Note	
ie010ral	01 Oral	1		
ie02Nasal	02 Nasal	2		
ie03Inhaled	03 Inhaled	3		
ie04Vein	04 Shot up - vein	4		
ie05Muscle	05 Shot up - muscle	5		
ie06Skin	06 Shot up - skin	6		
ie07Tongue	07 Dissolved under tongue	7		
ie08Topical	08 Topical	8		
ie09Rectal	09 Rectal	9		
ie10Vaginal	10 Vaginal	10		

Pulldown List 4:				
RefName	Display Text	Value	Design Note	
ie010ral	01 Oral	1		
ie02Nasal	02 Nasal	2		
ie03Inhaled	03 Inhaled	3		
ie04Vein	04 Shot up - vein	4		
ie05Muscle	05 Shot up - muscle	5		
ie06Skin	06 Shot up - skin	6		
ie07Tongue	07 Dissolved under tongue	7		
ie08Topical	08 Topical	8		
ie09Rectal	09 Rectal	9		
ie10Vaginal	10 Vaginal	10		

Pulldown List 5:					
RefName	Display Text	Value	Design Note		
ie010ral	01 Oral	1			
ie02Nasal	02 Nasal	2			
ie03Inhaled	03 Inhaled	3			
ie04Vein	04 Shot up - vein	4			
ie05Muscle	05 Shot up - muscle	5			
ie06Skin	06 Shot up - skin	6			
ie07Tongue	07 Dissolved under tongue	7			
ie08Topical	08 Topical	8			
ie09Rectal	09 Rectal	9			
ie10Vaginal	10 Vaginal	10			

Pulldown List 6:				
RefName	Display Text	Value	Design Note	
ie010ral	01 Oral	1		
ie02Nasal	02 Nasal	2		
ie03Inhaled	03 Inhaled	3		
ie04Vein	04 Shot up - vein	4		
ie05Muscle	05 Shot up - muscle	5		
ie06Skin	06 Shot up - skin	6		
ie07Tongue	07 Dissolved under tongue	7		
ie08Topical	08 Topical	8		
ie09Rectal	09 Rectal	9		
ie10Vaginal	10 Vaginal	10		

Pulldown List 7:					
Display Text	Value	Design Note			
01 Oral	1				
02 Nasal	2				
03 Inhaled	3				
04 Shot up - vein	4				
05 Shot up - muscle	5				
	Display Text 01 Oral 02 Nasal 03 Inhaled 04 Shot up - vein	Display Text Value 01 Oral 1 02 Nasal 2 03 Inhaled 3 04 Shot up - vein 4			

Annotated Trial Design Page 40 of 68

ie06Skin	06 Shot up - skin	6	
ie07Tongue	07 Dissolved under tongue	7	
ie08Topical	08 Topical	8	
ie09Rectal	09 Rectal	9	
ie10Vaginal	10 Vaginal	10	

Pulldown L	Pulldown List 8:		
RefName Display Text		Value	Design Note
ie010ral	01 Oral	1	
ie02Nasal	02 Nasal	2	
ie03Inhaled	03 Inhaled	3	
ie04Vein	04 Shot up - vein	4	
ie05Muscle	05 Shot up - muscle	5	
ie06Skin	06 Shot up - skin	6	
ie07Tongue	07 Dissolved under tongue	7	
ie08Topical	08 Topical	8	
ie09Rectal	09 Rectal	9	
ie10Vaginal	10 Vaginal	10	

Pulldown List 9:			
RefName	Display Text	Value	Design Note
ie010ral	01 Oral	1	
ie02Nasal	02 Nasal	2	
ie03Inhaled	03 Inhaled	3	
ie04Vein	04 Shot up - vein	4	
ie05Muscle	05 Shot up - muscle	5	
ie06Skin	06 Shot up - skin	6	
ie07Tongue	07 Dissolved under tongue	7	
ie08Topical	08 Topical	8	
ie09Rectal	09 Rectal	9	
ie10Vaginal	10 Vaginal	10	

Pulldown List 10:			
RefName	Display Text	Value	Design Note
ie010ral	01 Oral	1	
ie02Nasal	02 Nasal	2	
ie03Inhaled	03 Inhaled	3	
ie04Vein	04 Shot up - vein	4	
ie05Muscle	05 Shot up - muscle	5	
ie06Skin	06 Shot up - skin	6	
ie07Tongue	07 Dissolved under tongue	7	
ie08Topical	08 Topical	8	
ie09Rectal	09 Rectal	9	
ie10Vaginal	10 Vaginal	10	

Pulldown List 11:				
RefName	Display Text	Value	Design Note	
ie010ral	01 Oral	1		
ie02Nasal	02 Nasal	2		
ie03Inhaled	03 Inhaled	3		
ie04Vein	04 Shot up - vein	4		
ie05Muscle	05 Shot up - muscle	5		
ie06Skin	06 Shot up - skin	6		
ie07Tongue	07 Dissolved under tongue	7		
ie08Topical	08 Topical	8		
ie09Rectal	09 Rectal	9		
ie10Vaginal	10 Vaginal	10		

Column Data Type	Design Note	
NUMERIC		
STRING(255) - A255		
STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10		
NUMERIC		
STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10		
NUMERIC		
STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10		
NUMERIC	NUMERIC	
NUMERIC		
STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10		
NUMERIC		
	STRING(255) - A255 STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 NUMERIC STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 NUMERIC STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 NUMERIC NUMERIC NUMERIC STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10	

Annotated Trial Design Page 41 of 68

TFB005B	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10	
TFB006A	NUMERIC	
TFB006B	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10	
TFB007A	NUMERIC	
TFB007B	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10	
TFB008A	NUMERIC	
TFB008B	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10	
TFB003A	NUMERIC	
TFB003B	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10	
TFB002A	NUMERIC	
TFB002B	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10	
VISITDT	DATE	
TFB001	DATE - DDMONYYYY	
TFB001B	STRING(50) - A50	
TFB001C	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10	

Annotated Trial Design Page 42 of 68

ctn0027 : Vital Signs (VSF)		
1. Assessment Date	Req V / Req V / Req W (2006-2010) (CTN0027CDD: LfrVSF.VISITDT)	
Vital Signs		
2. 1. Time	Req Req 24-hour clock (00:00 to 23:59) (CTN0027CDD:t_frVSF.VSF001)	
3. 2. Temperature:	XXXX. (CTN0027CDD:t_frVSF.VSF002)	
4. 3. Blood pressure:	xxx	
5. 4. Pulse:	xxx	
6. 5. Respirations:	spirations: $ xx $	
7. 6. Weight	XXXXXX (CTN0027CDD:t_frVSF.VSF006) (CTN0027CDD:t_frVSF.VSF006A) (1] 0 1 lb (2] 0 2 kg	

CDD: CTN0027CDD	Table: t_frVSF Ke	y Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
VSF006	NUMERIC - N5	
VSF006A	NUMERIC	
VISITDT	DATE - DDMONYYYY	
VSF001	DATE - HHMM	
VSF002	FLOAT - F5.0	
VSF002A	NUMERIC	
VSF003A	NUMERIC - N3	
VSF003B	NUMERIC - N3	
VSF004	NUMERIC - N3	
VSF005	NUMERIC - N2	

Annotated Trial Design Page 43 of 68

ct	n0027 : Alcohol Breathalyzer (ABZ)				
Ald	Alcohol Breathalyzer				
1.		CTN0027CDD:t_frABZ.AB001) CD O No To O No Req			
2.*	2. Comments:	(CTN0027CDD:t_frABZ.AB002)			
*	¹ Item is not required				

CDD: CTN0027CDD Table: t_frABZ Key Type: PATIENTVISIT				
Column Name	Column Data Type	Design Note		
AB001	NUMERIC			
AB001A	DATE - DDMONYYYY			
AB001B	FLOAT - F5.3			
AB002	STRING(200) - A200			

Annotated Trial Design Page 44 of 68

ct	ctn0027 : Randomization (RAN)			
Ra	ndomization			
1.*	Date of randomization: [read-only]			
2.*	Randomization number: [read-only]	XXXXX (CTN0027CDD:t_frRAN.INF003)		
3.*	Treatment Group [read-only]	CTN0027CD0:1_FRAN INFO04) 11		
4.*	Liver Test Result [read-only]	CTN0027CDD: L_fRAN.INF005) 11 O Normal		
5.	Are Date of randomization, Randomization number, Treatment Group, and Liver Test Result items complete and accurate?	(CTN0027CDD:1_frRan INF006) [1] ○ Yes [0] ○ No		
*	Item is not required			

CDD: CTN0027CDD	Table: t_frRAN K	ey Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
INF005	NUMERIC	
INF006	NUMERIC	
INF002	DATE - DDMONYYYY	
INF003	NUMERIC - N4	
INF004	NUMERIC	

Annotated Trial Design Page 45 of 68

#	Assessment Date	Date:	Location	Total dose received	Location	
000						
Assessment Date Req / Req (2006-2010) (CTN0027CDD:t_frDOS.VISITDT)						
lease record daily dose	of study drug that was dispensed to participant.					
Date:		Req ▼ / Req ▼ / Req ▼ (2006-2010) (CTN0027CDD:LfrD0S.DOS001)				
. Drug (check only one):	Drug (check only one): (CTN0027CDD:t_frDos.DoSo02) [1]					
Total dose received: xxx mg (CTN0027CDD:t_frDOS.DOS005)						
Drug administration location:				(CTN0027CDD:t_frDOS.DOS006) [1] OClinic [2] OHome		

CDD: CTN0027CDD	Table: t_frDOS	Key Ty	pe: PATIENTVISIT
Column Name	Column Data Typ	e	Design Note

Column Name	Column Data Type	Design Note
DOS005	NUMERIC - N3	
DOS006	NUMERIC	
DOS002	NUMERIC	
VISITDT	DATE - DDMONYYYY	
DOS001	DATE - DDMONYYYY	

ctn0027 : Clinical Opiate Withdrawal Scale - Predose (COWS1)				
1. Assessment Date				
r or each item, mark the choice that best describes the patient's signs or symptom. Rate on just the apparent relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging just prior to assessment, the increased pulse rate would not add to the score.				
2. 1. Resting pulse rate: measured after patient is sitting or lying for one minute:	Pulldown List 1 (CTN0027CDD:t_frcOWS.COWS001) Actual pulse rate: xxx			
3. 2. Gl upset: over the last 1/2 hour:	Pulldown List 2 ♥ (CTN0027CDD: t_frCOWS.COWS002)			
4. 3. Sweating: over the past 1/2 hour not accounted for by room temperature or patient activity:	Pulldown List 3 v (CTN0027CDD: t_frCOWS.COWS003)			
5. 4. Tremor: observation of outstretched hands:	Pulldown List 4 v (CTN0027CDD: t_frCOWS.COWS004)			
6. 5. Restlessness: observation during assessment:	Pulldown List 5 🔽 (CTN0027CDD: t_frCOWS.COWS005)			
7. 6. Yawning: observation during assessment:	Pulldown List 6 ▼ (CTN0027CDD: L-frCOWS.COWS006)			
8. 7. Pupil size:	Pulldown List 7 ▼ (CTN0027CDD: L_frCOWS.COWS007)			
9. 8. Anxiety or irritability:	Pulldown List 8 ▼ (CTN0027CDD: t_frCOWS.COWS008)			
9. Bone or joint aches: If participant was having pain previously, only the additional component attributed to opiate withdrawal is scored:	Pulldown List 9 v (CTN0027CDD: L_frCOWS.COWS009)			
11. 10. Gooseflesh skin:	Pulldown List 10 v CTN0027CDD: t_rcOWS.COWS010)			
12. 11. Runny nose or tearing: not accounted for by cold symptoms or allergies:	Pulldown List 11 vi (CTN0027CDD: t_rCOWS.COWS011)			
12. Total score (the total score is the sum of all 11 itmes): [read-only]	(CTN0027CDD:t_frCOWs.COWS012)			
13. Initials of Evaluator:	A3 (CTN0027CDD:t_frcOWS.COWS012a)			

Pulldown List 1:				
RefName	Display Text	Value	Design Note	
ieRPR0	0 Pulse rate 80 or below	0		
ieRPR1	1 Pulse rate 81 - 100	1		
ieRPR2	2 Pulse rate 101 - 120	2		
ieRPR4	4 Pulse rate greater than 120	4		

Pulldown List 2:				
RefName	Display Text	Value	Design Note	
ieGIUP0	0 No GI symptoms	0		
ieGIUP1	1 Stomach cramps	1		
ieGIUP2	2 Nausea or loose stool	2		
ieGIUP3	3 Vomiting or diarrhea	3		
ieGIUP5	5 Multiple episodes of diarrhea or vomiting	5		

Pulldown List 3:				
RefName	Display Text	Value	Design Note	
ieSWET0	0 No report of chills or flushing	0		
ieSWET1	1 Subjective report of chills or flushing	1		
ieSWET2	2 Flushed or observable moisture on face	2		
ieSWET3	3 Beads of sweat on brow or face	3		
ieSWET4	4 Sweat streaming off face	4		

Pulldown List 4:			
RefName	Display Text	Value	Design Note
ieTREM0	0 No tremor	0	
ieTREM1	1 Tremor can be felt, but not observed	1	
ieTREM2	2 Slight tremor observable	2	
ieTREM4	4 Gross tremor or muscle twitching	4	

Pulldown List 5:				
RefName	Display Text	Value	Design Note	
ieRSTL0	0 Able to sit still	0		
ieRSTL1	1 Reports difficulty sitting still, but is able to do so	1		
ieRSTL2	2 Frequently shifting or extraneous movements of legs/arms	2		
ieRSTL3	3 Unable to sit still for more than a few seconds	3		

Pulldown List 6:			
RefName	Display Text	Value	Design Note
ieYAWN0	0 No yawning	0	
ieYAWN1	1 Yawning once or twice during assessment	1	
ieYAWN2	2 Yawning three or more times during assessment	2	
ieYAWN4	4 Yawning several times/minute	4	

Pulldown List 7:				
RefName	Display Text	Value	Design Note	
iePUPL0	0 Pupils pinned abnormal size for room light	0		
iePUPL1	1 Pupils possibly larger than normal for room light	1		
iePUPL2	2 Pupils moderately dilated	2		
iePUPL5	5 Pupils so dilated that only the rim of the iris is visible	5		

Page 46 of 68

Annotated Trial Design Page 47 of 68

Pulldown	Pulldown List 8:				
RefName	Display Text	Value	Design Note		
ieANX0	0 None	0			
ieANX1	1 Participant reports increasing irritability or anxiousness	1			
ieANX2	2 Participant obviously irritable or anxious	2			
ieANX4	4 Participant is rubbing joints and muscles and is unable to sit still because of discomfort	4			

Pulldown List 9:				
RefName	Display Text	Value	Design Note	
ieBONA0	0 Not present	0		
ieBONA1	1 Mild diffuse discomfort	1		
ieBONA02	2 Participant reports severe diffuse aching of joints/muscle	2		

Pulldown List 10:			
RefName	Display Text	Value	Design Note
ieGOOS0	0 Skin is smooth	0	
ieGOOS3	3 Piloerection of skin can be felt or hairs standing up on arms	3	
ieGOOS5	5 Prominent piloerection	5	

Pulldown List 11:			
RefName	Display Text	Value	Design Note
ieRUNY0	0 Not present	0	
ieRUNY1	1 Nasal stuffiness or unusually moist eyes	1	
ieRUNY4	4 Nose constantly running or tears streaming down cheeks	4	

CDD: CTN0027CDD	Table: t_frCOWS Key T	ype: PATIENTV
Column Name	Column Data Type	Design Note
COWS002	STRING(255) - 0, 1, 2, 3, 5	
COWS003	STRING(255) - 0, 1, 2, 3, 4	
VISITDT	DATE - DDMONYYYY	
COWS001	STRING(255) - 0, 1, 2, 4	
COWS001a	NUMERIC - N3	
COWS004	STRING(255) - 0, 1, 2, 4	
COWS005	STRING(255) - 0, 1, 2, 3	
COWS006	STRING(255) - 0, 1, 2, 4	
COWS007	STRING(255) - 0, 1, 2, 5	
COWS008	STRING(255) - 0, 1, 2, 4	
COWS009	STRING(255) - 0, 1, 2	
COWS010	STRING(255) - 0, 3, 5	
COWS011	STRING(255) - 0, 1, 4	
COWS012	STRING(255)	
COWS012a	STRING(3) - A3	

ctn0027 : Clinical Opiate Withdrawal Scale - Postdose (COWS2)					
Assessment Date	Req / Req /				
reach item, mark the choice that best describes the patient's signs or symptom. Rate on just the apparent relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging just prior to assessment, the increased pulse rate would not add to the score.					
1. Resting pulse rate: measured after patient is sitting or lying for one minute: xxxx (n >= 0) (CTN0027CDD:t_frC0WS2.COWS2001a)					
3. 2. Gl upset: over the last 1/2 hour:	Pulldown List 2 \(\subseteq \text{ (CTN0027CDD:t_frCOWS2.COWS002)} \)				
4. 3. Sweating: over the past 1/2 hour not accounted for by room temperature or patient activity:	Pulldown List 3 (CTN0027CDD:t_frCOWS2.COWS003)				
5. 4. Tremor: observation of outstretched hands:	Pulldown List 4 (CTN0027CDD:t_frCOWS2.COWS004)				
6. 5. Restlessness: observation during assessment:	Pulldown List 5 (CTN0027CDD:t_frCOWS2.COWS005)				
7. 6. Yawning: observation during assessment:	Pulldown List 6 V (CTN0027CDD:t_frC0Ws2.COWS006)				
8. 7. Pupil size:	Pulldown List 7 💟 (CTN0027CDD:t_frC0Ws2.COWS007)				
9. 8. Anxiety or irritability:	Pulldown List 8 V (CTN0027CDD:t_frC0Ws2.COWS008)				
10. 9. Bone or joint aches: If participant was having pain previously, only the additional component attributed to opiate withdrawal is scored:	Pulldown List 9 (CTN0027CDD:t_frC0Ws2.COWS009)				
11. 10. Gooseflesh skin:	Pulldown List 10 W CTN0027CDD:t_frC0WS2.C0WS010)				
12. 11. Runny nose or tearing: not accounted for by cold symptoms or allergles:	Pulldown List 11 V CTN0027CDD:L_frC0WS2.C0WS011)				
12. Total score (the total score is the sum of all 11 itmes): [read-only]	(CTN0027CDD:L_frC0WS2.C0WS012)				
13. Initials of Evaluator:	A3 (CTN0027CDD:t_frcOWS2.COWS012a)				

Pulldown List 1:				
RefName	Display Text	Value	Design Note	
ieRPR0	0 Pulse rate 80 or below	0		
ieRPR1	1 Pulse rate 81 - 100	1		
ieRPR2	2 Pulse rate 101 - 120	2		
ieRPR4	4 Pulse rate greater than 120	4		

Pulldown List 2:				
RefName	Display Text	Value	Design Note	
ieGIUP0	0 No GI symptoms	0		
ieGIUP1	1 Stomach cramps	1		
ieGIUP2	2 Nausea or loose stool	2		
ieGIUP3	3 Vomiting or diarrhea	3		
ieGIUP5	5 Multiple episodes of diarrhea or vomiting	5		

Pulldown List 3:				
RefName	Display Text	Value	Design Note	
ieSWET0	0 No report of chills or flushing	0		
ieSWET1	1 Subjective report of chills or flushing	1		
ieSWET2	2 Flushed or observable moisture on face	2		
ieSWET3	3 Beads of sweat on brow or face	3		
ieSWET4	4 Sweat streaming off face	4		

Pulldown List 4:				
RefName	Display Text	Value	Design Note	
ieTREM0	0 No tremor	0		
ieTREM1	1 Tremor can be felt, but not observed	1		
ieTREM2	2 Slight tremor observable	2		
ieTREM4	4 Gross tremor or muscle twitching	4		

Pulldown List 5:				
RefName	Display Text	Value	Design Note	
ieRSTL0	0 Able to sit still	0		
ieRSTL1	1 Reports difficulty sitting still, but is able to do so	1		
ieRSTL2	2 Frequently shifting or extraneous movements of legs/arms	2		
ieRSTL3	3 Unable to sit still for more than a few seconds	3		

Pulldown List 6:				
RefName	Display Text	Value	Design Note	
ieYAWN0	0 No yawning	0		
ieYAWN1	1 Yawning once or twice during assessment	1		
ieYAWN2	2 Yawning three or more times during assessment	2		
ieYAWN4	4 Yawning several times/minute	4		

Pulldown List 7:					
RefName	Display Text	Value	Design Note		
iePUPL0	0 Pupils pinned abnormal size for room light	0			
iePUPL1	1 Pupils possibly larger than normal for room light	1			
iePUPL2	2 Pupils moderately dilated	2			
iePUPL5	5 Pupils so dilated that only the rim of the iris is visible	5			

Page 48 of 68

Annotated Trial Design Page 49 of 68

Pulldown List 8:					
RefName	Display Text	Value	Design Note		
ieANX0	0 None	0			
ieANX1	1 Participant reports increasing irritability or anxiousness	1			
ieANX2	2 Participant obviously irritable or anxious	2			
ieANX4	4 Participant is rubbing joints and muscles and is unable to sit still because of discomfort	4			

Pulldown List 9:				
RefName	Display Text	Value	Design Note	
ieBONA0	0 Not present	0		
ieBONA1	1 Mild diffuse discomfort	1		
ieBONA02	2 Participant reports severe diffuse aching of joints/muscle	2		

Pulldown List 10:						
RefName	Display Text	Value	Design Note			
ieGOOS0	0 Skin is smooth	0				
ieGOOS3	3 Piloerection of skin can be felt or hairs standing up on arms	3				
leGOOS5	5 Prominent piloerection	5				

Pulldown List 11:					
RefName	Value	Design Note			
ieRUNY0	0 Not present	0			
ieRUNY1	1 Nasal stuffiness or unusually moist eyes	1			
ieRUNY4	4 Nose constantly running or tears streaming down cheeks	4			

CDD: CTN0027CDD	Table: t_frCOWS2 Key T	ype: PATIENT
Column Name	Column Data Type	Design Note
COWS2001a	NUMERIC - N3	
COWS002	STRING(255) - 0, 1, 2, 3, 5	
COWS003	STRING(255) - 0, 1, 2, 3, 4	
COWS006	STRING(255) - 0, 1, 2, 4	
COWS007	STRING(255) - 0, 1, 2, 5	
COWS008	STRING(255) - 0, 1, 2, 4	
COWS009	STRING(255) - 0, 1, 2	
COWS010	STRING(255) - 0, 3, 5	
COWS011	STRING(255) - 0, 1, 4	
COWS012	STRING(255)	
COWS012a	STRING(3) - A3	
COWS004	STRING(255) - 0, 1, 2, 4	
COWS005	STRING(255) - 0, 1, 2, 3	
VISITDT	DATE - DDMONYYYY	
COWS001	STRING(255) - 0, 1, 2, 4	

Annotated Trial Design Page 50 of 68

tn0027 : Pregnancy and Birth Control Assessment (PBC							
. Assessment Date	Req V Req V Req V Req V (2006-2010) (CTN0027CDD:t_fr9BC.VISITDT)						
complete this form only for females.							
. Was a pregnancy test performed?	(CTN0027CDD: <u>L</u> fPBC.PBC001) [O] ○ 0 No [1] ○ 1 Ves						
* Date of pregnancy test:	Req / Req (2006-2010) (CTN0027CDD:t_frPBC.PBC002)						
* Pregnancy test result:	(CTN0027CDP: LfrPBC.PBC003) [1]						
.* Comments:	A200 (CTN0027CDD:_frPBC.PBC006)						
* Item is not required							

CDD: CTN0027CDD	Table: t_frPBC Key	Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
PBC003a	NUMERIC	
PBC006	STRING(200) - A200	
PBC001	NUMERIC	
VISITDT	DATE - DDMONYYYY	
PBC002	DATE - DDMONYYYY	
PBC003	NUMERIC	

Annotated Trial Design Page 51 of 68

Ot.	0027 : Prior and Concomitant Medications (PCM)											
Pric	r and Concomitant Medications											
1.*	Has the participant taken any medications during the assessment period? (SCR = last 2 weeks, other visits = since last PCM assessment) [hidden]	(CTN0027CDD:t_frPCM.PCM001) [0] 0 No [1] 0 1 Yes, Complete below.										
	Con Med No.	Medication Name		Indicatio	n Amount	t Units Spec	er	Specify Rout Other Freq	Specify Other Route	Medicatio Start Date	Medication End Date	Continuing
2.												
2.a	Con Med No.		xxx (CTN0027CDD:t_frPCM.PCM002)									
2.b	▲ Generic Name of Medication (refer to QT Prolongation Drug List)		A30 (CTN0027CDD:t_frPCM.l	PCM002A)								
2.c	<u>B</u> Indication		A30 (CTN0027CDD:t_frPCM.l	CM002B)								
2.d	C Amount		xxxxxxxx. (CTN0027CDD:t_frPCM.PCM002C)									
2.e	<u>D</u> Units		Pulldown List 1 (CTN0027CDD:t_frPCM.PCM002E)									
2.f*	Specify Other Units		A20 (CTN0027CDD:t_frPCM.PCM002ES)								
2.g	<u>E</u> Freq		Pulldown List 2 (CTN0027CDD: t_frPCM.PCM002F)									
2.h	Specify Other Freq		A20 (CTN0027CDD: t_frPCM.PCM002FS)								
2.i	E Route		Pulldown List 3 (CTN0027CDD:t_frPCM.PMC002G)									
2.j*	Specify Other Route		A20 (CTN0027CDD: t_frPCM.PCM002FG	S)								
2.k	G Medication Start Date		NReq / NReq / Req (1950-2010) (CTN002	7CDD: t_frPCM.PC	M002H)							
2.1*	H Medication End Date		Req / Req / Req (1950-2010) (CTN0027C	DD:t_frPCM.PCM0	021)							
2.m	· L Continuing		(CTN0027CDD:t_frPCM.PCM002J) [1] 1 Continuing									

Pulldown List 1:					
RefName	Display Text	Value	Design Note		
ie01Capsule	A=capsule	1			
ie02Drop	B=drop	2			
ie03Grain	C=grain	3			
ie04gram	D=gram	4			
ie05Microgram	E=microgram	5			
ie06Microliter	F=microliter	6			
ie07Milligram	G=milligram	7			
ie08Milliliter	H=milliliter	8			
ie09Ounce	I=ounce	9			
ie10Patch	J=patch	10			
ie11Puff	K=puff	11			
ie12Spray	L=spray/ squirt	12			
ie13Suppository	M=suppository	13			
ie14Tablespoon	N=tablespoon	14			
ie15Other	O=other (specify)	15			

Pulldown List 2:						
RefName	Display Text	Value	Design Note			
ie01qd	01 qd	1				
ie02bid	02 bid	2				
ie03tid	03 tid	3				
ie04qid	04 qid	4				
ie05qod	05 qod	5				
ie06qhs	06 qhs	6				
ie07contIV	07 cont. IV	7				
ie08prn	08 prn	8				
ie09q4h	09 q4h	9				
ie10q6h	10 q6h	10				
ie11q8h	11 q8h	11				
ie12q12h	12 q12h	12				
ie13x1	13 x 1	13				
ie140ther	14 Other (specify	14				

Pulldown List 3:						
RefName	Display Text	Value	Design Note			
ie1PO	1 PO	1				
ie2IV	2 IV	2				
ie3SC	3 SC	3				
ie41M	4 IM	4				
ie51Vbolus	5 IV bolus	5				
ie6Sublingual	6 Sublingual	6				

Annotated Trial Design Page 52 of 68

ie7Inhaled	7 Inhaled	7	
ie8Topical	8 Topical	8	
ie9Other	9 Other (specify)	9	

CDD: CTN0027CDD Table: t_frPCM Key Type: PATIENTVISIT							
Column Name	Column Data Type	Design Note					
PCM002ES	STRING(20) - A20						
PCM002F	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14						
PCM002FS	STRING(20) - A20						
PCM001	NUMERIC						
PMC002G	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9						
PCM002FGS	STRING(20) - A20						
PCM002H	DATE - DDMONYYYY						
PCM002I	DATE - DDMONYYYY						
PCM002J	STRING(255)						
PCM002B	STRING(30) - A30						
PCM002C	FLOAT - F8.0						
PCM002E	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15						
VISITDT	DATE						
PCM002	NUMERIC - N3						
PCM002A	STRING(30) - A30						

Annotated Trial Design Page 53 of 68

Week #	Assessment Date	AE Number	Adverse Event	Onset Date	Severity	Action taken	Study Drug Related	Expected?	Serious AE?	Outcome	End Date or Ongoing
,						1.			1		
Veek #						xx (-1 =< n <= 32)	(CTN0027CDD:t_frAE.VSWKAE)				
ssessment Date						Req 🗸 / Req 🗸 / Req 🗸	(2006-2010) (CTN0027CDD:t_frAE.VS	DTAE)			
E Number						A3 (CTN0027CDD:t_frAE.AE	(002)				
dverse Event						A200	(CTN0027CDD:t_frAE.AE003)				
nset Date						Req 🗸 / Req 🗸 / Req 🗸	(2006-2010) (CTN0027CDD: t_frAE.AE	003A)			
everity						Pulldown List 1 (CTN00270	CDD: t_frAE.AE004)				
ction taken (chec						(CTN0027CDD:_t_rAE_AE005a) [7]					
	d? (check only one)						2 Possibly [3] 03 Probably [4]	○ 4 Definitely			
xpected?						(CTN0027CDD:t_frAE.AE007) [0] 0 No [1] 1 Yes					
erious Adverse E	vent?					(CTN0027CDD:1_fr4E.AE008) [0] ○ 0 No [1] ○ 1 Yes					
Outcome						(CTN0027CDD:1_frAE.AE009) [1] ①1 Resolved [2] ②2 Resolved with sequelae [3] ③3 Not resolved [4] ④4 Death					
nd Date or Ongoi	ng					(CTN0027CDD:t_frAE.AE011)	Req / Req (2006-2010) (CTI	NO027CDD-t frAF AF010)	111 ○1 Ongoing		

Pulldown List 1:									
RefName	Display Text	Value	Design Note						
ieSEVR1	1 Mild	1							
ieSEVR2	2 Moderate	2							
ieSEVR3	3 Severe	3							
ieSEVR4	4 Life-threatening	4							
ieSEVR5	5 Death	5							

CDD: CTN0027CDD Table: t_frAE Key Type: PATIENTVISIT						
Column Name	Column Data Type	Design Note				
VSDTAE	DATE - DDMONYYYY					
VSWKAE	NUMERIC - N2					
AE002	STRING(3) - A3					
AE003	STRING(200) - A200					
AE004	STRING(255) - 1, 2, 3, 4, 5					
AE005a	STRING(255)					
AE005b	STRING(255)					
AE005c	STRING(255)					
AE005d	STRING(255)					
AE005e	STRING(255)					
AE005f	STRING(255)					
AE005g	STRING(255)					
AE005h	STRING(255)					
AE005i	STRING(255)					
AE006	NUMERIC					
AE007	NUMERIC					
AE008	NUMERIC					
AE009	NUMERIC					
AE011	NUMERIC					
AE003A	DATE - DDMONYYYY					
AE010	DATE - DDMONYYYY					

Annotated Trial Design Page 54 of 68

n0027 : Genetics (GEN)	
Assessment Date	Req 💟 / Req 💟 / Req 💟 (2006-2010) (CTN0027CDD:t_frGEN.VISITDT)
Does the participant agree to participate in the Genetics Study?	(CTN0027CDD:L_frGEN.GEN001) [0] ○No [1] ○Yes
Date Informed Consent Signed:	NReq 💟 / NReq 💟 / NReq 💟 (2006-2010) (CTN0027CDD:t_frGEN GEN002)
Genetics Study ID (Unique I dentifier)	A7 (CTN0027CDD: t_frGEN.GEN008)
mple Obtained	
Week 2 (blood) Taken:	Date: NReq ♥ / NReq ♥ / NReq ♥ (2006-2010) (CTN0027CDD: t_frGEN.GEN003a) Time: NReq ♥ : NReq ♥ 24-nour clock (CTN0027CDD: t_frGEN.GEN003b)
Was the sample shipped?	(CTN0027CDD:L_frGEN.GEN004) [0]
Week 12 (blood and urine) Taken:	Date: NReq
Were the samples shipped?	(CTN0027CDD:L_frGEN.GEN006) [0] ○No [1] ○Yes
Participant withdrew consent:	(CTN0027CDD:t_frGEN.GEN007) [0] No [1] Yes NReq / NReq (2006-2010) (CTN0027CDD:t_frGEN.GEN007d)
Item is not required	·

CDD: CTN0027CDD	Table: t_frGEN Key	Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
GEN008	STRING(7) - A7	
GEN003a	DATE - DDMONYYYY	
VISITDT	DATE - DDMONYYYY	
GEN001	NUMERIC	
GEN002	DATE - DDMONYYYY	
GEN007d	DATE - DDMONYYYY	
GEN003b	DATE - HHMM	
GEN004	NUMERIC	
GEN005a	DATE - DDMONYYYY	
GEN005b	DATE - HHMM	
GEN006	NUMERIC	
GEN007	NUMERIC	

Annotated Trial Design Page 55 of 68

ctr	0027 · Sei	rious Ad	verse Event (SA	AE) - Repeating Form	1										
#				Adverse Event Number		SAE Name (name of event)	SAE Description	SAE Onset Date	SAE Resolution Date	SAE Categorization	Severity of SAE	SAE actions taken	Relationship to Study Drug	Was event expected?	SAE Outcome
1	3														
	2														
1.*	Calculated Se	equence Nun	nber (this should be hid	dden) [hidden]		(CTN0027CDD:t_frSAE.S	SEQNUMGEN)								
2.*	Seq Num (at	utomatic) [r	ead-only]			xx (CTN0027CDD:t_fr	SAE.SEQNUM)								
3.	Week #					xx (-1 =< n <=	32) (CTN0027CDD	o: t_frSAE.VISWKAE)							
4.	Assessment	Date				Req 🗸 / Req 🗸 / Re	(2006-2010)	(CTN0027CDD:t_frSA	E.VSDTAE)						
Ser	ous Adverse E	vent													
5.	Adverse Eve		•			xxx CTN0027CDD: t_f									
6.	1. Type of R	eport				(CTN0027CDD:t_frSAE.S [1]	SAE001) Follow-Up Follow	v up number xxx	(CTN0027CDD:t_frSAE.SAEC	01a)					
7.	2. SAE Name (name of eve					A200	(C	CTN0027CDD:t_frSAE.	.SAE002)						
8.	3. SAE Desc	ription				A500		(СТ	N0027CDD: t_frSAE.SAE003)					
9.	4. SAE Onse					Req / Req / Req									
10.	SAE Reso SAE Categ		'			Req ▼ / Req ▼ / Re (CTN0027CDD:t_frSAE.S		(C1N0027CDD:t_frSA	E.SAE005)						
12	7 Saverity,	of SAF					:AEOO6b)	[1] 0 1 Yes ehab) [0] 0 N 0 [1] 0 1 Yes 1 [1] 0 1 Yes (CTN0027: 1. Anoma (CTN0027: 3. Aborte (CTN0027: 4. Stillbir (CTN0027: 5. Infant	Swer 1 through 5 CDD::frSAE.SAE006e1) aly [0] © 0 No [1] CDD::frSAE.SAE006e2) riage [0] © 0 No [1] CDD::frSAE.SAE006e3) d [0] © 0 No [1] © 1 CDD::frSAE.SAE006e4) th. [0] © 0 No [1] CDD::frSAE.SAE006e5) death within 1 month of	1 Yes Yes 1 Yes Uffe [0] 0 No [1]	○ 1 Yes				
12.	7. Severity of (check only of					(CTN0027CDD:t_frSAE.S [1] 0 1 Mild [2] 0	AE007) 2 Moderate [3] (3 Severe [4] O	4 Life-threatening [5]	5 Death					
13.	8. SAE actio (check all tha	ns taken at apply)				(CTN0027CDD:t_frSAE.S [1]	AE0082) drug dose (> 24 hou AE0083)	[4]	CDD:t_frSAE.SAE0084) Reduced study drug dose CDD:t_frSAE.SAE0085) Discontinued study drug ten CDD:t_frSAE.SAE0086) Discontinued study drug per		(CTN0027CDD: t_f [7]	inued Meth rSAE.SAE0088)			
14.	9. Relations (check only o	hip to Stud ne):	y Drug			(CTN0027CDD:t_frSAE.S [1] O1 Unrelated [AE009) 2] 02 Possibly [3] O 3 Probably [74] 04 Definitely						
15.	10. Was eve	ent expecte	d?		<u> </u>	(CTN0027CDD:t_frSAE.S [0] 0 No [1] 01				<u> </u>		<u> </u>			
16.	11. SAE Out	come				(CTN0027CDD: t_frSAE.S [1]	sequelae	▼ / NReq ▼ / NRe	eq	27CDD:t_frSAE.SAE011a)	1				
*	tem is not re	auired	-	-			-	-	-		-				

CDD: CTN0027CDD Table: t_frSAE Key Type: PATIENTVISIT

	.,,	
Column Name	Column Data Type	Design Note
VSDTAE	DATE - DDMONYYYY	
SAE00A	NUMERIC - N3	
SAE001	NUMERIC	
SAE009	NUMERIC	
SAE010	NUMERIC	
SAE011	NUMERIC	
SAE006e2	NUMERIC	
SAE006e3	NUMERIC	
SAE006e4	NUMERIC	
SAE001a	NUMERIC - N3	

Annotated Trial Design Page 56 of 68

SAE002	STRING(200) - A200	
SAE003	STRING(255) - A500	
SAE004	DATE - DDMONYYYY	
SAE005	DATE - DDMONYYYY	
SAE006a	NUMERIC	
SAE006b	NUMERIC	
SAE006c	NUMERIC	
SAE006d	NUMERIC	
SAE007	NUMERIC	
SAE0087	STRING(255)	
SAE0088	STRING(255)	
SAE006e	NUMERIC	
SAE006e1	NUMERIC	
SAE006e5	NUMERIC	
SAE006f	NUMERIC	
SAE0081	STRING(255)	
SAE0082	STRING(255)	
SAE0083	STRING(255)	
SAE0084	STRING(255)	
SAE0085	STRING(255)	
SAE0086	STRING(255)	
SEQNUMGEN	STRING(255)	
SAE011a	DATE - DDMONYYYY	
SEQNUM	NUMERIC - N2	
VISWKAE	NUMERIC - N2	

Annotated Trial Design Page 57 of 68

# Seq Num Assessment Date	Drug Name	Lot Number	Expiration Date	Quantity Administered	Start Date	Date Last Taken	Tests/Data/Dates		
Seq Num		xx (CTN0027CDD: t_frSAE2a.:	SEQNUM)						
Assessment Date		Req / Req / Req (2006-2010) (CTN0027CDD:t_frSAE2a.	VSDTAE)					
erious Adverse Event (continued)		<i>'</i>							
* 12. Study Drug Name		(CTN0027CDD:t_frSAE2a.SAE012) [1] ① 1 Methadone [2] ② 2 Buprenorphine (BUP)							
* Study Drug Lot Number		A50 (CTN0027CDD:t_frSAE2a.SAE012a)							
* Study Drug Expiration Date		Req / Req (2006-2011) (CTN0027CDD:t_frSAE2a.SAE012b) month / year							
* Quantity of Study Drug Administered		mg (buprenorphine dosed by sublingual tablet once daily: methadone dose by ingestion) (CTN0027CDD:L_frSAE2a.SAE012c)							
* Study Drug Start Date		Req V / Req V / Req V (2006-2010) (CTN0027CDD:L_frSAE2a.SAE012d)							
* Date Study Drug Last Taken		Req / Req / Req (2006-2010) (CTN0027CDD:t_frSAE2a.SAE012e)							
* 13. Relevant tests/laboratory data, including dates	A200 (CTN0027CDD: LfrSAE2a.SAE013)								

CDD: CTN0027CDD	Table: t_frSAE2a	Key Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
SEQNUM	NUMERIC - N2	
VSDTAE	DATE - DDMONYYYY	
SAE012	NUMERIC	
SAE012a	STRING(50) - A50	
SAE012b	DATE - MONYYYY	
SAE012c	NUMERIC - N3	
SAE012d	DATE - DDMONYYYY	
SAE012e	DATE - DDMONYYYY	
SAE013	STRING(200) - A200	

Annotated Trial Design Page 58 of 68

ct	n0027 : Se	rious Adverse	Event (continued) (SAE2b) - Repeatir	g Form					
	# Seq.Num Assessment Date		Assessment Date	Concomitant Drug Therapy					
1		0							
L									
1.	Seq Num			XX (CTN0027CDE	D: t_frSAE2b.SEQNUM)				
2.	Assessment [Date		Req V / Req V	Req V / Req V (2006-2010) (CTN0027CDD:t_frSAE2b.VSDTAE)				
	Drug			Quantity					
3.									
C	oncomitant Dru	g Therapy Entry							
3.	14a. Drug	(including generic n	name)	A1	00	(CTN0027CDD: t_frSAE2b.SAE014a)			
3.	14b. Quant	ity per Administrati	ion	A1	00	(CTN0027CDD: t_frSAE2b.SAE014b)			
3.	* 14c. Route	of Administration		A1	00	(CTN0027CDD:t_frSAE2b.SAE014c)			
*	Item is not re	equired		·					

CDD: CTN0027CDD	Table: t_frSAE2b Key T	ype: PATIENTVISIT
Column Name	Column Data Type	Design Note
VSDTAE	DATE - DDMONYYYY	
SAE014a	STRING(100) - A100	
SAE014b	STRING(100) - A100	
SAE014c	STRING(100) - A100	
SEQNUM	NUMERIC - N2	

Annotated Trial Design Page 59 of 68

	Seq Num	Assessment Date	Relevant History	Comments	Site Clinician	Phone Number	Email	SAE reporter	Clinician signed	Safety Monitor	Safety Monitor signed		
000													
Seq Num													
Asse	ssment Date					Req	/ Req / Req	(2006-2010) (CTN0027CDD	t_frSAE3.VSDTAE)				
rious A	dverse Event (continued)												
	elevant history, includin unction, etc.):	g date of consent and pre-existi	ing medical conditons (e.g. aller	gies, pregnancy, smoking	and alcohol use, hepatic/r	renal A200	A200 (CTN0027CDD:t_frSAE3.SAE015)						
16. A	dditional Comments:					A200	A200 (CTN0027CDD:t_frSAE3.SAE016)						
17a.	Site Medical Clinician's I	lame:				A50	A50 (CTN0027CDD:t_frSAE3.SAE017a)						
17b.	Phone Number:					(xxx	(xxx) (CTN0027CDD:t_frSAE3.SAE017b1) - xxx (CTN0027CDD:t_frSAE3.SAE017b2) xxxx (CTN0027CDD:t_frSAE3.SAE017b3)						
17c.	Email:					A50	A50 (CTN0027CDD:t_frSAE3.SAE017c)						
17d.	SAE reporter's Name					A50	A50 (CTN0027CDD:t_frSAE3.SAE017d)						
9. 17e. Site Medical Clinician's signature date:					NReq	NReq / NReq / NReq (2006-2010) (CTN0027CDD:t_frSAE3.SAE017e2)							
17f. S	Study Safety Monitor's n	ame			A50 (CTN0027CDD:t_frSAE3.SAE017f)								
11. 17g. Study Safety Monitor's signature date NReq / NReq (2006-2010) (CTN0027CDD:t_frSAE3.SAE017g2)													

CDD: CTN0027CDD	Table: t_frSAE3 Key	Type: PATIENTVISI
Column Name	Column Data Type	Design Note
SAE017f	STRING(50) - A50	
SAE017g2	DATE - DDMONYYYY	
SEQNUM	NUMERIC - N2	
VSDTAE	DATE - DDMONYYYY	
SAE015	STRING(200) - A200	
SAE016	STRING(200) - A200	
SAE017a	STRING(50) - A50	
SAE017b1	NUMERIC - N3	
SAE017b2	NUMERIC - N3	
SAE017b3	NUMERIC - N4	
SAE017c	STRING(50) - A50	
SAE017d	STRING(50) - A50	
SAE017e2	DATE - DDMONYYYY	

Annotated Trial Design Page 60 of 68

ctr	10027 : Pregnancy and Outcome (POC)	
	Assessment Date	
2.	Week Number	$ \begin{array}{llllllllllllllllllllllllllllllllllll$
Sec	tion I: Information about Pregnancy	
3.	1. Who discovered the pregnancy?	(CTN0027CDD:1_frPOC.POC001) [1] ①1 Study Participant [2] ②2 Study Staff [96] ③NA
4.	2. How was the pregnancy verified?	(CTN0027CDD:t_frPOC.rgPOC002a) [93]
5.	3. Date on which the pregnancy was verified:	(CTN0027CDD:t_frP0C.rgP0C003) [99] Req / Req / Req (2006-2010) (CTN0027CDD:t_frP0C.P0C003) [96] NA
6.	4. Date on which study staff was aware of pregnancy:	(CTN0027CDD:t_frP0C.rgP0C004) [99]
7.	5. Date on which study medication was discontinued:	(CTN0027CDD: t_frPOC.rgPOC005) T991 Req / Req / Req (2006-2010) (CTN0027CDD: t_frPOC.POC005) [96] NA
8.	6. Approximate due date:	(CTN0027CDD::_frPOC.rgPOC006) [99] Req / Req / Req (2006-2010) (CTN0027CDD::_frPOC.POC006) [96] NA
Sec	tion II: Outcome of Pregnancy	
9.	7. Outcome of Pregnancy:	CTN0027CDD: L_frP0C.POC007) 17
10.	8. Date of Delivery:	(CTN0027CDD:_frPOC.rgPOC008) Teq
11.	9. Number of live births - this pregnancy?	(CTN0027CDD:t_frP0C.P0C009) [0] © 9.a if 0 live births, indicate reason: (CTN0027CDD:t_frP0C.P0C009a) [1] © 1 [2] © 2 [3] © 3 [96] © NA A100
12.	10. Type of Delivery	(CTN0027CDD:1_frP0C.P0C010) [1] ①1 Vaginal [2] ②2 Cesarean Section [96] ◎NA

CDD: CTN0027CDD	Table: t_frPOC Key	Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
rgPOC004	NUMERIC	
VISITDT	DATE - DDMONYYYY	
rcVSFRNUM	NUMERIC	
tcVSFRNUM	NUMERIC - N3	
POC001	NUMERIC	
rgPOC002a	NUMERIC	
POC002a	STRING(255)	
POC002b	STRING(255)	
POC002c	STRING(255)	
rgPOC003	NUMERIC	
POC008	DATE - DDMONYYYY	
POC009	NUMERIC	
POC009a	STRING(100) - A100	
POC004	DATE - DDMONYYYY	
rgPOC005	NUMERIC	
POC005	DATE - DDMONYYYY	
rgPOC006	NUMERIC	
POC006	DATE - DDMONYYYY	
POC007	NUMERIC	
POC007a	STRING(100) - A100	
POC007b	STRING(100) - A100	
rgPOC008	NUMERIC	
POC010	NUMERIC	
POC003	DATE - DDMONYYYY	

Annotated Trial Design Page 61 of 68

ctr	n0027 : Pregnancy and Outcome Contd (POC NB)												
1.	Assessment Date	Req / Req (2006-2010) (CTN002	27CDD:t_frPOC1A.VISITDT)										
2.	Week Number	(CTN0027CDD:t_frP0C1A.rcVSFRNUM) [99] ○ xxx											
	Gender	Weeks		Days Lb	s Ozs	Length	Circumference	Score:	Score	R APGAR Score: 24 hrs	Normal Specify	Contributing factors	
3.													
Nev	wborn Information Entry												
3.a	Gender		(CTN0027CDD:t_frPOC1A.POC011a) [1]										
3.b	Gestational age at delivery: Weeks		(CTN0027CDD:t_frPOC1A.rgPOC011b1) [99]	○ NA									
3.c	Gestional age at delivery: Days		(CTN0027CDD:t_frP0C1A.rgP0C011b2) [99] x Days (CTN0027CDD:t_frP0C1A.P0C011b2) [96]	NA									
3.d	Weight: lbs		(CTN0027CDD:_t_frPOC1A.rgP0C011c1) [99]										
3.e	Weight: ozs		(CTN0027CDD:t_frP0C1A:rgP0C011c2) [99] ○ xx ozs (CTN0027CDD:t_frP0C1A:P0C011c2) [96] ○ NA										
3.f	Length		(CTN0027CDD: t_frP0C1A.rgP0C011d) [99]										
3.g	Head circumference		(CTN0027CDD::L_frP0C1A.rgP0C011e) [99] xx cm (CTN0027CDD::L_frP0C1A.P0C011e) [96] NA										
3.h	APGAR Score: 1 min		(CTN0027CDD:t_frPOC1A.rgPOC011f1) [99]) NA									
3.i	APGAR Score: 5 min		(CTN0027CDD:t_frPOC1A.rgPOC011f2) [99]) NA									
3.j	APGAR Score: 24 hrs		(CTN0027CDD:t_frP0C1A.rgP0C011f3) [99] xx 24 hrs (CTN0027CDD:t_frP0C1A.P0C011f3) [96] () NA									
3.k	Normal Infant?		(CTN0027CDD:1_frPOC1A.POC011g) [O] ○No [1] ○Yes [196] ○NA										
3.1	If No, specify abnormality:		(CTN0027CDD:t_frPOC1A.rgPOC011g1) [99]	POC011g1)	[96]	/ ONA							
3.m	Contributing factors to abnormality		$ \begin{array}{c c} (\texttt{CTN0027CDD:} \bot \texttt{frPOC1A.rgPOC011g2}) \\ \textbf{[99]} & \bigcirc \middle \texttt{A200} & \middle (\texttt{CTN0027CDD:} \bot \texttt{frPOC1A.} \\ \end{array} $	POC011g2)	[96]	7 ○NA							
lf m	ore than 3 babies, record physical characteristics and any abnormality and contributing factors in comments.												
4.*	14. Comments:	(CTN0027CDD: t_frPOC1A.rgPOC012) [99]	(CTN0027CDD:t_frPOC1A.POC012) [96]										
*	Item is not required												

CDD: CTN0027CDD	Table: t frPOC1A K	(ey Type: PATIENTVIS
Column Name		
	Column Data Type	Design Note
POC011d	NUMERIC - N2	
rgPOC011e	NUMERIC	
POC011e	NUMERIC - N2	
rcVSFRNUM	NUMERIC	
tcVSFRNUM	NUMERIC - N3	
POC011a	NUMERIC	
rgPOC011b1	NUMERIC	
POC011b1	NUMERIC - N2	
rgPOC011b2	NUMERIC	
POC011b2	NUMERIC - N1	
rgPOC011c1	NUMERIC	
POC011c2	NUMERIC - N2	
rgPOC011f1	NUMERIC	
POC011f1	NUMERIC - N2	
rgPOC011f2	NUMERIC	
POC011f2	NUMERIC - N2	
rgPOC011f3	NUMERIC	
rgPOC011g2	NUMERIC	
POC011g2	STRING(200) - A200	
POC011f3	NUMERIC - N2	
POC011g	NUMERIC	
rgPOC011g1	NUMERIC	
POC011g1	STRING(200) - A200	
rgPOC012	NUMERIC	
POC012	STRING(200) - A200	

Annotated Trial Design Page 62 of 68

VISITDT	DATE - DDMONYYYY	
POC011c1	NUMERIC - N2	
rgPOC011c2	NUMERIC	
rgPOC011d	NUMERIC	

Annotated Trial Design Page 63 of 68

ctn	0027 :	Protoco	ol Violation (PVL) -	Repeating Form									
-	# <u>Week.# Assessment Date</u> <u>PV Date</u> 4 Violation Type				4 Violation Type	PV Resolved? Comments pe							
1	000												
1.	Week #					The state of the s	(-1 =< n <= 32) (CTN0027CDD:t_frPVL.VI						
2.	Assessn	nent Date				Req	/ Req / Req (2006-2010) (CTN0027CI	DD:t_frPVL.VISITDT)					
To b	e filled ir	n by person	n(s) reporting this protocol	violation:									
3.	Date of	violation:				Req	/ Req / Req (2006-2010) (CTN0027CI	DD:t_frPVL.PVL001)					
4. Violation Type:							Pulldown List 1 CTN0027CDD:t_frPVL.PVL002) If Other is indicated, please provide the specification: (CTN0027CDD:t_frPVL.PVL002A) A50						
5.	Descript	ion of viol	ation:			A200	A200 (CTN0027CDD: t_frPVL.PVL003)						
6. Has this Protocol Violation been resolved?						(CTNO)	(CTN0027CDD: t_frPVL.PVL004) [O] No [1] 1 1 Yes - If Yes: Indicate resolution below. (CTN0027CDD: t_frPVL.PVL005) Protocol violation resolution: A255						
7.* Comments:							A255 (CTN0027CDD:t_frPVL.PVL006)						
* 1	tem is n	em is not required											

Pulldown List 1:								
RefName	Display Text	Value	Design Note					
iePV_01	01A-No consent/assent obtained	1						
iePV_02	01B-Invalid/incomplete informed consent	2						
iePV_03	01C-Unauthorized assessments and/or procedures conducted prior to obtaining informed consent	3						
iePV_04	01D-Informed Consent Other (specify)	4						
iePV_05	02-Inclusion/Exclusion Criteria	5						
iePV_06	03-Concomitant Medication/Therapy	6						
iePV_07	04A-Required testing not obtained	7						
iePV_08	048-Testing completed outside window	8						
iePV_09	04C-Unauthorized test/procedure obtained	9						
iePV_10	04D-Laboratory Assessments/ Procedures Other (specify)	10						
iePV_11	05A-Protocol required procedures not obtained	11						
iePV_12	05B-Procedure/ assessment obtained outside visit window/ timeframe	12						
iePV_13	05C-Study Procedures Other (specify)	13						
iePV_14	06A-SAE not reported	14						
iePV_15	06B-SAE reported out of time window	15						
iePV_16	06C-Serious Adverse Event Other (specify)	16						
iePV_17	07A-Randomization procedures not followed	17						
iePV_18	07B-Ineligible participant randomized	18						
iePV_19	07C-Improper un-blinding procedures	19						
iePV_20	07D-Randomization Procedures Other (specify)	20						
iePV_21	08A-Ineligible participant dispensed (given) medication	21						
iePV_22	08B-Incorrect medication dispensed (given to participant)	22						
iePV_23	08C-Incorrect medication dosage or amount of medication dispensed (given to participant)	23						
iePV_24	08D-Study Drug Dosing Other (specify)	24						
iePV_25	09A-Intervention not provided per protocol schedule or outside visit window/ timeframe	25						
iePV_26	09B-Incorrect Intervention Assignment	26						
iePV_27	09C-Behavioral Intervention Other (specify)	27						
iePV_28	10A-Visit conducted outside of window	28						
iePV_29	99A-Destroying study materials prior to obtaining authorization from Lead Node and/or other appropriate parties	29						
iePV_30	99B-Participating site starting the study prior to obtaining appropriate IRB(s) and/or CT approvals and any other approvals that would affect the ability to use the data for final analysis	30						
iePV_31	99C-Using advertising materials or brochures without prior IRB approval;	31						
iePV_99	99D-Other (specify)	99						

CDD: CTN00270	CDD Table: t_frPVL Key Type: PATIENTVISIT	
Column Name	Column Data Type	Design Note
PVL005	STRING(255) - A255	
PVL006	STRING(255) - A255	
VISWEEK	NUMERIC - N2	
VISITDT	DATE - DDMONYYYY	
PVL001	DATE - DDMONYYYY	
PVL002	STRING(255) - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 99	
PVL002A	STRING(50) - A50	
PVL003	STRING(200) - A200	

Annotated Trial Design Page 64 of 68

PVL004 NUMERIC

Annotated Trial Design Page 65 of 68

ct	0027 : Study Medication Change Form (MED)					
1.	Week #	$ xx $ (-1 =< n <= 32) (CTN0027CDD:t_frDIS.VISWEEK)				
2.	Assessment Date	Req / Req (2006-2010) (CTN0027CDD:t_frDIS.VISITDT)				
Ina	ctive Status:					
3.		(CTN0027CDD: L_frDIS.DIS003) [1] ○ 1-Methadone [2] ○ 2-Buypenorphine\Naloxone Date: Req ▼ / Req ▼ / Req ▼ (2006-2010) (CTN0027CDD: L_frDIS.dcDIS003)				
4.	2. Reason for medication change (check all that apply):	(CTN0027CDD: t_frDIS.DIS004b) [7]				
5.*	3. Comments:	A200 (CTN0027CDD:t_frDIS.DIS005)				
* Item is not required						

CDD: CTN0027CDD	Table: t_frDIS Key	Type: PATIENTVISIT
Column Name	Column Data Type	Design Note
DIS004b	STRING(255)	
DIS004c	STRING(255)	
DIS004c1	STRING(255)	
DIS004c2	STRING(255)	
DIS004c3	STRING(255)	
DIS004c4	STRING(255)	
DIS005	STRING(200) - A200	
VISWEEK	NUMERIC - N2	
VISITDT	DATE - DDMONYYYY	
DIS003	NUMERIC	
dcDIS003	DATE - DDMONYYYY	

Annotated Trial Design Page 66 of 68

Week #	xx
Assessment Date	Req ✓ / Req ✓ / Req ✓ (2006-2010) (CTN0027CDD: t_frTERM.VISITDT)
Did participant complete the study?	(CTN0027CDD:t_frTERM.TER001) [0] No [1] Ves, specify date: Req / Req (2006-2010) (CTN0027CDD:t_frTERM.dcTER001)
Whose decision was it to withdraw/terminate?	(CTN0027CDD:t_frTERM.TER002) [1] Onvestigator's decision [2] OParticipant's Decision [96] ONA
Reason for withdrawal/termination (Check only one Reason):	CTRODYCOD LETEM TRODGS [1] Screen Failure (Check all that apply) (CTRO027CDD LETEM TEROGSa) [1] If
Last Study Drug Dose Date:	(CTN0027CDD:t_frTERM.TER004) [2] NReq / NReq / NReq (2006-2010) (CTN0027CDD:t_frTERM.dcTER004) [96] NA
Did participant complete termination visit?	(CTN0027CDD:1_frTERM.TER005) [7]

CDD: CTN0027CDD	Table: t_frTERM Key Type: PATIENTVIS	
Column Name	Column Data Type	Design Note
VISWEEK	NUMERIC - N2	ĺ
TER003fs	STRING(30) - A30	
TER003g	STRING(255)	
TER003c	STRING(255)	
TER003fa	STRING(255)	ĺ
TER003fb	STRING(255)	ĺ
TER03fc1	STRING(255)	
TER03fc2	STRING(255)	
TER03fc3	STRING(255)	
TER03fc4	STRING(255)	ĺ
TER003fd	STRING(255)	
TER003fe	STRING(255)	
TER003ff	STRING(255)	
TER003fg	STRING(255)	
TER003fh	STRING(255)	
TER003fi	STRING(255)	
TER003e	STRING(255)	
TER003f	STRING(255)	
TER003gs	STRING(30) - A30	
TER003na	STRING(255)	
TER004	NUMERIC	
dcTER004	DATE - DDMONYYYY	
TER005	NUMERIC	
TER001	NUMERIC	

Annotated Trial Design Page 67 of 68

dcTER001	DATE - DDMONYYYY	
TER002	NUMERIC	
TER003a	STRING(255)	
TER003aa	STRING(255)	
TER003ab	STRING(255)	
TER003ac	STRING(255)	
TER003b	STRING(255)	
TER003d	STRING(255)	
VISITDT	DATE - DDMONYYYY	

Annotated Trial Design Page 68 of 68